U.S. patent application number 10/746314 was filed with the patent office on 2005-02-10 for indole derivatives.
This patent application is currently assigned to Bayer Aktiengesellschaft. Invention is credited to Bischoff, Hilmar, Faeste, Christiane, Haning, Helmut, Kretschmer, Axel, Schmidt, Gunter, Vohringer, Verena, Woltering, Michael.
Application Number | 20050032874 10/746314 |
Document ID | / |
Family ID | 26008111 |
Filed Date | 2005-02-10 |
United States Patent
Application |
20050032874 |
Kind Code |
A1 |
Haning, Helmut ; et
al. |
February 10, 2005 |
Indole derivatives
Abstract
The invention relates to new indole derivatives, processes for
their preparation, and their use in medicaments.
Inventors: |
Haning, Helmut; (Wuppertal,
DE) ; Woltering, Michael; (Wuppertal, DE) ;
Schmidt, Gunter; (Wuppertal, DE) ; Bischoff,
Hilmar; (Wuppertal, DE) ; Kretschmer, Axel;
(Wuppertal, DE) ; Vohringer, Verena; (Wuppertal,
DE) ; Faeste, Christiane; (Haan, DE) |
Correspondence
Address: |
JEFFREY M. GREENMAN
BAYER PHARMACEUTICALS CORPORATION
400 MORGAN LANE
WEST HAVEN
CT
06516
US
|
Assignee: |
Bayer Aktiengesellschaft
Leverkusen
DE
D 51368
|
Family ID: |
26008111 |
Appl. No.: |
10/746314 |
Filed: |
December 23, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10746314 |
Dec 23, 2003 |
|
|
|
10026023 |
Dec 21, 2001 |
|
|
|
6794406 |
|
|
|
|
Current U.S.
Class: |
514/418 ;
548/484 |
Current CPC
Class: |
A61P 5/14 20180101; A61P
3/10 20180101; C07D 209/08 20130101; A61P 9/04 20180101; A61P 29/02
20180101; A61P 9/06 20180101; C07D 403/12 20130101; A61P 11/00
20180101; C07D 405/12 20130101; A61P 3/06 20180101; A61P 9/10
20180101; A61P 25/28 20180101; A61P 19/10 20180101; C07D 417/12
20130101; A61P 25/24 20180101; A61P 3/04 20180101; A61P 17/14
20180101; A61P 35/00 20180101; A61P 25/04 20180101; A61P 17/00
20180101 |
Class at
Publication: |
514/418 ;
548/484 |
International
Class: |
A61K 031/404; C07D
209/36 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 27, 2000 |
DE |
10065433.9 |
Jun 27, 2001 |
DE |
10130830.2 |
Claims
1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Cancelled).
14. (Cancelled).
15. A method for the treatment and/or prophylaxis of
arteriosclerosis and hypercholesterol aemia comprising
administering to a subject in need thereof an effective amount of a
compound of Formula I 185in which Z represents O, S, SO, SO.sub.2,
CH.sub.2, CHF, CF.sub.2 or represents NR.sup.9, in which R.sup.9
denotes hydrogen or (C.sub.1l-C.sub.4)-alkyl, R.sup.1 and R 2 are
identical or different and represent hydrogen, halogen, cyano,
(C.sub.1-C.sub.6)-alkyl, CF.sub.3, CHF.sub.2, CH.sub.2F, vinyl or
(C.sub.3-C.sub.7)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and in the ortho position to
the bridge bond, R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10, in which A represents
O, S, NR.sup.11 or represents the group
--(CR.sup.12.ident.CR.sup.13)--, in which R.sup.11 denotes hydrogen
or (C.sub.1-C.sub.4)-alkyl, and R.sup.12 and R.sup.13 are identical
or different and denote hydrogen, cyano, (C.sub.1-C.sub.4)-alkyl or
(C.sub.1-C.sub.4)-alkoxy, D represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono-(C.sub.1-C.sub.4)-alkylamino,
mono-(C.sub.1-C.sub.4)-acylamino or
(C.sub.1-C.sub.4)-alkoxycarbonylamino, E and L independently of one
another represent a C(O) or SO.sub.2 group, G represents NR.sup.14,
in which R.sup.14 denotes hydrogen or (C.sub.1-C.sub.4)-alkyl, or
represents a straight-chain (C.sub.1-C.sub.3)-alkylene group, which
can be mono- or polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono- or di-(C.sub.1-C.sub.4)-alkylamino or
mono-(C.sub.1-C.sub.4)-acylamino, m, n, o and p independently of
one another in each case represent the number 0 or 1, with the
proviso that in the case that L represents a C.dbd.O-group, the sum
(m+n+o+p) is unequal to the number 0, and in the case that m and o
in each case represent the number 1, A represents the radical
NR.sup.11 and E and L in each case represent a C.dbd.O-group, the
sum (n+p) is unequal to the number 0, and R.sup.10 represents
OR.sup.15, NR.sup.16R.sup.17, (C.sub.1-C.sub.10)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl- , (C.sub.2-C.sub.6)-alkenyl,
(C.sub.6-C.sub.10)-aryl, (C.sub.6-C.sub.10-arylmethyl or represents
a saturated, partly unsaturated or aromatic 5- to 10-membered
heterocycle having up to four identical or different heteroatoms
from the group consisting of N, O and/or S, where the
abovementioned radicals are optionally substituted by one, two or
three identical or different substituents selected from the group
consisting of halogen, hydroxyl, oxo, cyano, nitro, amino,
NR.sup.18R.sup.19, trifluoromethyl, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkoxy optionally substituted by R.sup.20,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.6-C.sub.10)-aryl, which for
its part is optionally substituted by halogen,
(C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-alkoxy, trifluoromethyl,
nitro or cyano, --O--C(O)--R.sup.21, --C(O)--OR.sup.22,
--C(O)--NR.sup.23R.sup.24, --SO.sub.2--NR.sup.25R.sup.26,
--NH--C(O)--R.sup.27 and --NH--C(O)--OR.sup.28, where R.sup.15,
R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20, R.sup.21,
R.sup.22, R.sup.23, R.sup.24, R.sup.25, R.sup.26, R.sup.27 and
R.sup.28 are identical or different and in each case represent
hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.8)-cycloalkyl, which for their part are optionally
mono- or polysubstituted, identically or differently, by halogen,
hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C.sub.4)-alkoxycarbon- yl,
(C.sub.1-C.sub.4)-alkoxy-carbonylamino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl, or the group
-L-R.sup.10 represents a group of the formula 186in which R.sup.29
denotes hydrogen or (C.sub.1-C.sub.4-alkyl. or R.sup.3 represents a
group of the formula 187in which Q represents a 5- to 6-membered
saturated, partly unsaturated or aromatic heterocycle having up to
four identical or different heteroatoms from the group consisting
of N, O and/or S, which for its part is optionally mono- to
trisubstituted, identically or differently, by oxo (.dbd.O), thioxo
(.dbd.S), hydroxyl, (C.sub.1-C.sub.6)-alkyl or phenyl, r represents
the number 0, 1 or 2, and the ring Het denotes a 5- to 6-membered
saturated or partly unsaturated heterocycle having up to three
identical or different heteroatoms from the group consisting of N,
O and/or S, which is optionally mono- to trisubstituted,
identically or differently, by oxo (.dbd.O), thioxo (.dbd.S),
hydroxyl, (C.sub.1-C.sub.6)-alkyl or phenyl. R.sup.4 and R.sup.5
are identical or different and in each case represent hydrogen,
hydroxyl, halogen, cyano, nitro, (C.sub.1-C.sub.4)-alkyl or the
radical of the formula NR.sup.30R.sup.31, where R.sup.30 and
R.sup.31 have the meaning indicated for R.sup.15 and independently
of one another can be identical to or different from this
substituent, R.sup.6 represents hydrogen, halogen or represents a
group of the formula -M.sub.a-R.sup.32, in which M represents a
carbonyl group, a sulphonyl group or a methylene group, a
represents the number 0 or 1, and R.sup.32 has the meaning of
R.sup.10 indicated above and can be identical to or different from
this substituent, R.sup.7 represents hydrogen or represents an acyl
group which can be removed under physiological conditions with
formation of an NH function, preferably represents hydrogen or
acetyl, and R.sup.8 has the meaning of R.sup.6 indicated above and
can be identical to or different from this substituent, and their
pharmaceutically tolerable salts, solvates, hydrates and hydrates
of the salts.
16. A method for the prophylaxis and/or treatment of disease forms
which can be treated with natural thyroid hormone comprising
administering to a subject in need thereof an effective amount of a
compound of Formula I 188in which Z represents O, S, SO, SO.sub.2,
CH.sub.2, CHF, CF.sub.2 or represents NR.sup.9, in which R.sup.9
denotes hydrogen or (C.sub.1-C.sub.4)-alkyl, R.sup.1 and R.sup.2
are identical or different and represent hydrogen, halogen, cyano,
(C.sub.1-C.sub.6)-alkyl, CF.sub.3, CHF.sub.2, CH.sub.2F, vinyl or
(C.sub.3-C.sub.7)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and in the ortho position to
the bridge bond, R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10 in which A represents
O, S, NR.sup.11 or represents the group
--(CR.sup.12.dbd.CR.sup.13)--, in which R.sup.11 denotes hydrogen
or (C.sub.1-C.sub.4)-alkyl, and R.sup.12 and R.sup.13 are identical
or different and denote hydrogen, cyano, (C.sub.1-C.sub.4)-alkyl or
(C.sub.1-C.sub.4)-alkoxy, D represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono-(C.sub.1-C.sub.4)-alkylamino,
mono-(C.sub.1-C.sub.4)-acylamino or
(C.sub.1-C.sub.4)-alkoxycarbonylamino, E and L independently of one
another represent a C(O) or SO.sub.2 group, G represents NR.sup.14,
in which R.sup.14 denotes hydrogen or (C.sub.1-C.sub.4-alkyl, or
represents a straight chain (C.sub.1-C.sub.3-alkylene group, which
can be mono- or polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono- or di-(C.sub.1-C.sub.4)-alkylamino or
mono-(C.sub.1-C.sub.4-acylamino, m, n, o and p independently of one
another in each case represent the number 0 or 1, with the proviso
that in the case that L represents a C.dbd.O-group, the sum
(m+n+o+p) is unequal to the number 0, and in the case that m and o
in each case represent the number 1, A represents the radical
NR.sup.11 and E and L in each case represent a C.dbd.O-group, the
sum (n+p) is unequal to the number 0, and R.sup.10 represents
OR.sup.15, NR.sup.16R.sup.17, (C.sub.1-C.sub.10)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl- , (C.sub.2-C.sub.6)-alkenyl,
(C.sub.6-C.sub.10)-aryl, (C.sub.6-C.sub.10)-arylmethyl or
represents a saturated, partly unsaturated or aromatic 5- to
10-membered heterocycle having up to four identical or different
heteroatoms from the group consisting of N, O and/or S, where the
abovementioned radicals are optionally substituted by one, two or
three identical or different substituents selected from the group
consisting of halogen, hydroxyl, oxo, cyano, nitro, amino,
NR.sup.18R.sup.19, trifluoromethyl. (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkoxy optionally substituted by R.sup.20,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.6-C.sub.10)-aryl, which for
its part is optionally substituted by halogen,
(C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-alkoxy, trifluoromethyl,
nitro or cyano. --O--C(O)--R.sup.21, --C(O)--OR.sup.22,
--C(O)--NR.sup.23R.sup.24, --SO--NR.sup.25R.sup.26,
--NH--C(O)--R.sup.27 and --NH--C(O)--OR.sup.28, where R.sup.15,
R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20, R.sup.21,
R.sup.22, R.sup.23, R.sup.24, R.sup.25, R.sup.26, R.sup.27 and
R.sup.28 are identical or different and in each case represent
hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.8)-cycloalkyl, which for their part are optionally
mono- or polysubstituted, identically or differently, by halogen,
hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxy-carbonylamino,
(C.sub.1-C.sub.5-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl, or the group
-L-R.sup.10 represents a group of the formula 189in which R.sup.29
denotes hydrogen or (C.sub.1-C.sub.4-alkyl, or R.sup.3 represents a
group of the formula 190in which represents a 5- to 6-membered
saturated, partly unsaturated or aromatic heterocycle having up to
four identical or different heteroatoms from the group consisting
of N, O and/or S, which for its part is optionally mono- to
trisubstituted, identically or differently, by oxo (.dbd.O), thioxo
(.dbd.S), hydroxyl. (C.sub.1-C.sub.6)-alkyl or phenyl, r represents
the number 0, 1 or 2, and the ring Het denotes a 5- to 6-membered
saturated or partly unsaturated heterocycle having up to three
identical or different heteroatoms from the group consisting of N,
O and/or S, which is optionally mono- to trisubstituted,
identically or differently, by oxo (.dbd.O), thioxo (.dbd.S),
hydroxyl, (C.sub.1-C.sub.6)-alkyl or phenyl, R.sup.4 and R.sup.5
are identical or different and in each case represent hydrogen,
hydroxyl, halogen, cyano, nitro, (C.sub.1-C.sub.4)-alkyl or the
radical of the formula NR.sup.30R.sup.31, where R.sup.30 and
R.sup.31 have the meaning indicated for R.sup.15 and independently
of one another can be identical to or different from this
substituent, R.sup.6 represents hydrogen, halogen or represents a
group of the formula -M.sub.a-R.sup.32, in which M represents a
carbonyl soup, a sulphonyl group or a methylene group, a represents
the number 0 or 1, and R.sup.32 has the meaning of R.sup.10
indicated above and can be identical to or different from this
substituent, R.sup.7 represents hydrogen or represents an acyl
group which can be removed under physiological conditions with
formation of an Nil function, preferably represents hydrogen or
acetyl, and R.sup.8 has the meaning of R.sup.6 indicated above and
can be identical to or different from this substituent, and their
pharmaceutically tolerable salts, solvates, hydrates and hydrates
of the salts,
17. The method of claim 15 or 16, wherein the compound of Formula I
is administered in combination with other medicaments.
18. (Cancelled).
19. A process for the preparation of compounds of the Formula (I),
191in which Z represents O, S, SO, SO.sub.2, CH.sub.2, CHF,
CF.sub.2 or represents NR.sup.9, in which R.sup.9 denotes hydrogen
or (C.sub.1-C.sub.4-alkyl. R.sup.1 and R.sup.2 are identical or
different and represent hydrogen, halogen, cyano.
(C.sub.1-C.sub.6)-alkyl, CF.sub.3, CHF.sub.2CH.sub.2F, vinyl or
(C.sub.3-C.sub.7)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and in the ortho position to
the bridge bond, R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10, in which A represents
O, S, NR.sup.11 or represents the group
--(CR.sup.12.dbd.CR.sup.13)--, in which R.sup.11 denotes hydrogen
or (C.sub.1-C.sub.4)-alkyl, and R.sup.12 and R.sup.13 are identical
or different and denote hydrogen, cyano, (C.sub.1-C.sub.4)-alkyl or
(C.sub.1-C.sub.4)-alkoxy, D represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono-(C.sub.1-C.sub.4)-alkylami- no,
mono-(C.sub.1-C.sub.4)-acylamino or
(C.sub.1-C.sub.4)-alkoxycarbonylam- ino, E and L independently of
one another represent a C(O) or SO.sub.2 group, G represents
NR.sup.14, in which R.sup.14 denotes hydrogen or
(C.sub.1-C.sub.4)-alkyl, or represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono- or di-(C.sub.1-C.sub.4)-alkylamino or
mono-(C.sub.1-C.sub.4)-acylamino. m, n, o and p independently of
one another in each case represent the number 0 or 1, with the
proviso that in the case that L represents a C.dbd.O-group, the sum
(m+n+o+p) is unequal to the number 0, and in the case that m and o
in each case represent the number 1, A represents the radical
NR.sup.11 and E and L in each case represent a C.dbd.O-group, the
sum (n+p) is unequal to the number 0, and R.sup.10 represents
OR.sup.15, NR.sup.16R.sup.17, (C.sub.1-C.sub.10)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl- , (C.sub.2-C.sub.6)-alkenyl,
(C.sub.6-C.sub.10)-aryl, (C.sub.6-C.sub.10)-arylmethyl or
represents a saturated, partly unsaturated or aromatic 5- to
10-membered heterocycle having up to four identical or different
heteroatoms from the group consisting of N, O and/or S, where the
abovementioned radicals are optionally substituted by one, two or
three identical or different substituents selected from the group
consisting of halogen, hydroxyl, oxo, cyano, nitro, amino.
NR.sup.18R.sup.19, trifluoromethyl, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkoxy optionally substituted by R.sup.20,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.6-C.sub.10-aryl, which for its
part is optionally substituted by halogen, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkoxy, trifluoromethyl, nitro or cyano,
--O--C(O)--R.sup.21, --C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where R.sup.15, R.sup.16, R.sup.17,
R.sup.18, R.sup.19, R.sup.20, R.sup.21, R.sup.22, R.sup.23,
R.sup.24, R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are identical
or different and in each case represent hydrogen, phenyl, benzyl.
(C.sub.1-C.sub.6)-alkyl or (C.sub.3-C.sub.8)-cycloalkyl, which for
their part are optionally mono- or polysubstituted, identically or
differently, by halogen, hydroxyl, amino, carboxyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.1-C.sub.4)-alkoxycarbon- yl,
(C.sub.1-C.sub.4)-alkoxy-carbonylamino.
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl, or the group
-L-R.sup.10 represents a group of the formula 192in which R.sup.29
denotes hydrogen or (C.sub.1-C.sub.4-alkyl, or R.sup.3 represents a
group of the formula 193in which Q represents a 5- to 6-membered
saturated partly unsaturated or aromatic heterocycle having up to
four identical or different heteroatoms from the group consisting
of N, O and/or S, which for its part is optionally mono- to
trisubstituted, identically or differently, by oxo (.dbd.O) thioxo
(.dbd.O), hydroxyl, (C.sub.1-C.sub.6)-alkyl or phenyl, r represents
the number 0, 1 or 2, and the ring Het denotes a 5- to 6-membered
saturated or partly unsaturated heterocycle having up to three
identical or different heteroatoms from the group consisting of N,
O and/or S, which is optionally mono- to trisubstituted,
identically or differently, by oxo (.dbd.O), thioxo (.dbd.S),
hydroxyl, (C.sub.1-C.sub.6-alkyl or phenyl, R.sup.4 and R.sup.5 are
identical or different and in each case represent hydrogen,
hydroxyl, halogen, cyano, nitro. (C.sub.1-C.sub.4)-alkyl or the
radical of the formula NR.sup.30R.sup.31, where R.sup.30 and
R.sup.31 have the meaning indicated for R.sup.15 and independently
of one another can be identical to or different from this
substituent, R.sup.6 represents hydrogen, halogen or represents a
group of the formula -M.sub.a-R.sup.12, in which M represents a
carbonyl group, a sulphonyl group or a methylene group, a
represents the number 0 or 1, and R.sup.32 has the meaning of
R.sup.10 indicated above and can be identical to or different from
this substituent, R.sup.7 represents hydrogen or represents an acyl
group which can be removed under physiological conditions with
formation of an NH function, preferably represents hydrogen or
acetyl, and R.sup.8 has the meaning of R.sup.6 indicated above and
can be identical to or different from this substituent,
characterized in that reactive indole derivatives of the general
formula (II) are reacted with reactive phenyl derivatives of the
general formula (III) 194where the substituents R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 have the
meanings as defined above, and R.sup.3' has the meaning indicated
for R.sup.3 or represents NO.sub.2, NH.sub.2, NH--PG, OH, O--PG,
SH, S--PG, or represents an aldehyde, cyano, carboxyl or
(C.sub.1-C.sub.4)-alkoxy-carbonyl group, where PG represents a
protective group, X and Y in each case represent groups of opposite
reactivity, Z' has the meaning indicated for Z or represents
195optionally in the presence of inert solvents and catalysts and
optionally with isolation of the intermediates of the general
formula (IV) or directly to give compounds of the formula (I).
20. (Cancelled).
Description
[0001] The invention relates to new indole derivatives, processes
for their preparation and their use in medicaments.
[0002] In EP-A-580 550, oxamic acid derivatives are described which
have cholesterol-lowering properties in mammals. The reduction of
plasma cholesterol, in particular of LDL cholesterol, is emphasized
as a pharmacological property. Cholesterol-lowering actions are
also described in EP-A-188 351 for certain diphenyl ethers having
thyroid-hormone-like actions, which differ clearly in their
chemical structure from the compounds according to the
invention.
[0003] WO 00/51971 discloses oxamic acid derivatives having indole
partial structure as thyroid receptor ligands for the treatment of
various diseases.
[0004] Further indoles which are connected in the 5-position via a
bridge member having a substituted phenyl ring are known (WO
94/14770; EP-A-674 619 A1 or WO 94/26737). No thyroid-hormone-like
properties are described for these 5-substituted indoles.
[0005] WO 99/50268 discloses substituted indolealkanecarboxylic
acids which are suitable for the treatment of chronic complications
caused by diabetes mellitus.
[0006] WO 95/20588 discloses indole derivatives having action as
5-HT.sub.1 agonists.
[0007] WO 98/11895 discloses the use of 5-HT.sub.1 agonists for the
treatment of migraine; indole derivatives are also indicated as
suitable active compounds. In WO 98/06402, use for the treatment of
coryza or rhinitis is described for the same structures.
[0008] EP-A-639 573 discloses benzo-fused 5-membered ring
heterocycles and their use in medicaments and diagnostics. The
disclosed compounds are inhibitors of the cellular sodium-proton
antiporter (Na.sup.+/H.sup.+ exchanger).
[0009] U.S. Pat. No. 5,468,899 relates to bicyclic aryl compounds
having selective properties as LTB.sub.4 antagonists.
[0010] EP-A-377 450 discloses substituted indole, benzofuran and
benzothiophene derivatives having action as 5-lipoxygenase
inhibitors.
[0011] JP-A-07145 147 discloses testosterone 5-alpha-reductase
inhibitors derived from benzoic acid, which can be employed for the
treatment of prostate cancer and certain hair loss disorders.
[0012] In GB-A-2 253 848, phenylindole ethers di-ortho-substituted
in the phenyl moiety and having herbicidal action are described
which can be employed as crop protection agents. Thyromimetic
actions have hitherto not been published for these
ortho-substituted indoles.
[0013] The object of the invention is the provision of new
compounds having improved actions, in particular pharmaceutical
actions.
[0014] It has now been found that compounds of the general formula
(I) 1
[0015] in which
[0016] Z represents O, S, SO, SO.sub.2, CH.sub.2, CHF, CF.sub.2 or
represents NR.sup.9, in which R.sup.9 denotes hydrogen or
(C.sub.1-C.sub.4)-alkyl,
[0017] R.sup.1 and R.sup.2 are identical or different and represent
hydrogen, halogen, cyano, (C.sub.1-C.sub.6)-alkyl, CF.sub.3,
CHF.sub.2, CH.sub.2F, vinyl or (C.sub.3-C.sub.7)-cycloalkyl, where
at least one of the two substituents is unequal to hydrogen and in
the ortho position to the bridge bond,
[0018] R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10,
[0019] in which
[0020] A represents O, S, NR.sup.11 or represents the group
--(CR.sup.12.dbd.CR.sup.13)--, in which R.sup.11 denotes hydrogen
or (C.sub.1-C.sub.4)-alkyl, and R.sup.12 and R.sup.13 are identical
or different and denote hydrogen, cyano, (C.sub.1-C.sub.4)-alkyl or
(C.sub.1-C.sub.4)-alkoxy,
[0021] D represents a straight-chain (C.sub.1-C.sub.3)-alkylene
group, which can be mono- or polysubstituted, identically or
differently, by (C.sub.1-C.sub.4)-alkyl, hydroxyl,
(C.sub.1-C.sub.4)-alkoxy, halogen, amino,
mono-(C.sub.1-C.sub.4)-alkylamino, mono-(C.sub.1-C.sub.4)-acylamin-
o or (C.sub.1-C.sub.4)-alkoxycarbonylamino,
[0022] E and L independently of one another represent a C(O) or
SO.sub.2 group,
[0023] G represents NR.sup.14, in which R.sup.14 denotes hydrogen
or (C.sub.1-C.sub.4)-alkyl, or represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
polysubstituted, identically or differently, by
(C.sub.1-C.sub.4)-alkyl, hydroxyl, (C.sub.1-C.sub.4)-alkoxy,
halogen, amino, mono- or di-(C.sub.1-C.sub.4)-alkylamino or
mono-(C.sub.1-C.sub.4)-acylamino,
[0024] m, n, o and p independently of one another in each case
represent the number 0 or 1, with the proviso that in the case that
L represents a C.dbd.O group, the sum (m+n+o+p) is unequal to the
number 0,
[0025] and
[0026] in the case that m and o in each case represent the number
1, A represents the radical NR.sup.11 and E and L in each case
represent a C.dbd.O group, the sum (n+p) is unequal to the number
0,
[0027] and
[0028] R.sup.10 represents OR.sup.15, NR.sup.16R.sup.17,
(C.sub.1-C.sub.10)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.10)-arylmethyl or represents a saturated, partly
unsaturated or aromatic 5- to 10-membered heterocycle having up to
four identical or different heteroatoms from the group consisting
of N, O and/or S, where the abovementioned radicals are optionally
substituted by one, two or three identical or different
substituents selected from the group consisting of halogen,
hydroxyl, oxo, cyano, nitro, amino, NR.sup.18R.sup.19,
trifluoromethyl, (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy
optionally substituted by R.sup.20, (C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.6-C.sub.10)-aryl, which for its part is optionally
substituted by halogen, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkoxy, trifluoromethyl, nitro or cyano;
--O--C(O)--R.sup.21, --C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28,
[0029] where
[0030] R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20,
R.sup.21, R.sup.22, R.sup.23, R.sup.24, R.sup.25, R.sup.26,
R.sup.27 and R.sup.28 are identical or different and in each case
represent hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.8)-cycloalkyl, which for their part are optionally
mono- or polysubstituted, identically or differently, by halogen,
hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxy-carbonyl-amino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl,
[0031] or the group
[0032] -L-R.sup.10 represents a group of the formula 2
[0033] in which R.sup.29 denotes hydrogen or
(C.sub.1-C.sub.4)-alkyl,
[0034] or
[0035] R.sup.3 represents a group of the formula 3
[0036] in which
[0037] Q represents a 5- to 6-membered saturated, partly
unsaturated or aromatic heterocycle having up to four identical or
different hetero-atoms from the group consisting of N, 0 and/or S,
which for its part is optionally mono- to trisubstituted,
identically or differently, by oxo (.dbd.O), thioxo (.dbd.S),
hydroxyl, (C.sub.1-C.sub.6)-alkyl or phenyl,
[0038] r represents the number 0, 1 or 2,
[0039] and
[0040] the ring Het denotes a 5- to 6-membered saturated or partly
unsaturated heterocycle having up to three identical or different
heteroatoms from the group consisting of N, 0 and/or S, which is
optionally mono- to trisubstituted, identically or differently, by
oxo (.dbd.O), thioxo (.dbd.S), hydroxyl, (C.sub.1-C.sub.6)-alkyl or
phenyl,
[0041] R.sup.4 and R.sup.5 are identical or different and in each
case represent hydrogen, hydroxyl, halogen, cyano, nitro,
(C.sub.1-C.sub.4)-alkyl or the radical of the formula
NR.sup.30R.sup.31, where R.sup.30 and R.sup.31 have the meaning
indicated for R.sup.15 and independently of one another can be
identical to or different from this substituent,
[0042] R.sup.6 represents hydrogen, halogen or represents a group
of the formula
-M.sub.a-R.sup.32,
[0043] in which
[0044] M represents a carbonyl group, a sulphonyl group or a
methylene group,
[0045] a represents the number 0 or 1,
[0046] and
[0047] R.sup.32 has the meaning of R.sup.10 indicated above and can
be identical to or different from this substituent,
[0048] R.sup.7 represents hydrogen or represents an acyl group
which can be removed under physiological conditions with formation
of an NH function, preferably represents hydrogen or acetyl,
[0049] and
[0050] R.sup.8 has the meaning of R.sup.6 indicated above and can
be identical to or different from this substituent,
[0051] and their pharmaceutically tolerable salts, solvates,
hydrates and hydrates of the salts,
[0052] preferably the compounds which are trisubstituted, in
particular tetrasubstituted, in the phenyl moiety and preferably in
the 1-, 2-, 4- and 6-position and have a substituent in the
3-position in the indole ring,
[0053] exhibit a pharmacological action and can be used as
medicaments or for the preparation of pharmaceutical
formulations.
[0054] Heterocycles in the definition of R.sup.6, R.sup.8 or
R.sup.10 which may preferably be mentioned are:
[0055] A 5- to 10-membered saturated, partly unsaturated or
aromatic, optionally benzo-fused heterocycle having up to 4
heteroatoms from the group consisting of S, N and/or O, i.e. a
heterocycle, which can contain one or more double bonds and which
is linked via a ring carbon atom or a ring nitrogen atom. Examples
which may be mentioned are: tetrahydrofuryl, pyrrolidinyl,
pyrrolinyl, piperidinyl, 1,2-dihydro-pyridinyl,
1,4-dihydropyridinyl, piperazinyl, morpholinyl, azepinyl,
1,4-diazepinyl, (furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl,
imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl,
pyridazinyl, pyrimidinonyl, pyridazinonyl.
[0056] Preferred heterocycles from this list are: pyridyl,
pyrimidinyl, pyridazinyl, pyrimidinonyl, pyridazinonyl and
thienyl.
[0057] Alkyl in the context of the invention represents a
straight-chain or branched alkyl radical preferably having 1 to 15,
1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 3 carbon atoms. A
straight-chain or branched alkyl radical having 1 to 3 carbon atoms
is preferred. The following may be mentioned by way of example and
preferably: methyl, ethyl, n-propyl, isopropyl, n-, i-, s- or
t-butyl, n-pentyl and n-hexyl.
[0058] Aryl in the context of the invention represents an aromatic
radical preferably having 6 to 10 carbon atoms. Preferred aryl
radicals are phenyl and naphthyl.
[0059] Cycloalkyl in the context of the invention represents a
cycloalkyl group preferably having 3 to 8, 3 to 7 or 3 to 6 carbon
atoms. The following may be mentioned by way of example and
preferably: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl.
[0060] Alkoxy in the context of the invention preferably represents
a straight-chain or branched alkoxy radical having 1 to 6, 1 to 4
or 1 to 3 carbon atoms. A straight-chain or branched alkoxy radical
having 1 to 3 carbon atoms is preferred. The following may be
mentioned by way of example and preferably: methoxy, ethoxy,
n-propoxy, isopropoxy, t-butoxy, n-pentoxy and n-hexoxy.
[0061] Alkoxycarbonyl in the context of the invention preferably
represents a straight-chain or branched alkoxy radical having 1 to
6 or 1 to 4 carbon atoms, which is linked via a carbonyl group. A
straight-chain or branched alkoxycarbonyl radical having 1 to 4
carbon atoms is preferred. The following may be mentioned by way of
example and preferably: methoxycarbonyl, ethoxycarbonyl,
n-propoxycarbonyl, isopropoxycarbonyl and t-butoxycarbonyl.
[0062] Alkanoyloxy in the context of the invention preferably
represents a straight-chain or branched alkyl radical having 1 to
6, 1 to 5 or 1 to 3 carbon atoms, which in the 1-position carries a
doubly bonded oxygen atom and is linked in the 1-position via a
further oxygen atom. A straight-chain or branched alkanoyloxy
radical having 1 to 3 carbon atoms is preferred. The following may
be mentioned by way of example and preferably: acetoxy, propionoxy,
n-butyroxy, i-butyroxy, pivaloyloxy and n-hexanoyloxy.
[0063] Monoalkylamino in the context of the invention represents an
amino group having a straight-chain or branched alkyl substituent,
which preferably has 1 to 6, 1 to 4 or 1 to 2 carbon atoms. A
straight-chain or branched monoalkylamino radical having 1 to 4
carbon atoms is preferred. The following may be mentioned by way of
example and preferably: methylamino, ethylamino, n-propylamino,
isopropylamino, t-butylamino, n-pentylamino and n-hexylamino.
[0064] Dialkylamino in the context of the invention represents an
amino group having two identical or different straight-chain or
branched alkyl substituents, which preferably in each case have 1
to 6, 1 to 4 or 1 to 2 carbon atoms. Straight-chain or branched
dialkylamino radicals in each case having 1 to 4 carbon atoms are
preferred. The following may be mentioned by way of example and
preferably: N,N-dimethylamino, N,N-diethylamino,
N-ethyl-N-methylamino, N-methyl-N-n-propylamino,
N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino,
N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
[0065] Monoacylamino in the context of the invention represents an
amino group having a straight-chain or branched alkanoyl
substituent, which preferably has 1 to 6, 1 to 4 or 1 to 2 carbon
atoms and is linked via the carbonyl group. A monoacylamino radical
having 1 to 2 carbon atoms is preferred. The following may be
mentioned by way of example and preferably: formamido, acetamido,
propionamido, n-butyramido and pivaloylamido.
[0066] Alkoxycarbonylamino in the context of the invention
represents an amino group having a straight-chain or branched
alkoxycarbonyl substituent, which in the alkoxy radical preferably
has 1 to 6 or 1 to 4 carbon atoms and is linked via the carbonyl
group. An alkoxycarbonylamino radical having 1 to 4 carbon atoms is
preferred. The following may be mentioned by way of example and
preferably: methoxycarbonyl-amino, ethoxycarbonylamino,
n-propoxycarbonylamino and t-butoxycarbonylamino.
[0067] Halogen in the context of the invention includes fluorine,
chlorine, bromine and iodine. Fluorine, chlorine and bromine are
preferred.
[0068] Depending on the substituent pattern, the compounds
according to the invention can exist in stereoisomeric forms, which
either behave as image and mirror image (enantiomers), or which do
not behave as image and mirror image (diastereomers). The invention
relates both to the enantiomers or diastereomers and to their
respective mixtures. Like the diastereomers, the racemic forms can
be separated into the stereoisomerically uniform constituents in a
known manner.
[0069] Furthermore, certain compounds can be present in tautomeric
forms. This is known to the person skilled in the art, and
compounds of this type are likewise included by the scope of the
invention.
[0070] The compounds according to the invention can also be present
as salts. In the context of the invention, physiologically
acceptable salts are preferred.
[0071] Physiologically acceptable salts can be salts of the
compounds according to the invention with inorganic or organic
acids. Preferred salts are those with inorganic acids such as, for
example, hydrochloric acid, hydrobromic acid, phosphoric acid or
sulphuric acid, or salts with organic carboxylic or sulphonic acids
such as, for example, acetic acid, propionic acid, maleic acid,
fumaric acid, malic acid, citric acid, tartaric acid, lactic acid,
benzoic acid, or methanesulphonic acid, ethane-sulphonic acid,
benzenesulphonic acid, toluenesulphonic acid or
naphthalene-disulphonic acid.
[0072] Physiologically acceptable salts can likewise be salts of
the compounds according to the invention with bases, such as, for
example, metal or ammonium salts. Preferred examples are alkali
metal salts (e.g. sodium or potassium salts), alkaline earth metal
salts (e.g. magnesium or calcium salts), and ammonium salts, which
are derived from ammonia or organic amines, such as, for example,
ethylamine, di- or triethylamine, ethyldiisopropylamine,
monoethanolamine, di- or triethanolamine, dicyclohexyl-amine,
dimethylaminoethanol, dibenzylamine, N-methylmorpholine,
dihydroabietyl-amine, 1-ephenamine, methylpiperidine, arginine,
lysine, ethylenediamine or 2-phenylethylamine.
[0073] The compounds according to the invention can also be present
in the form of their solvates, in particular in the form of their
hydrates.
[0074] Moreover, the invention also includes prodrugs of the
compounds according to the invention. "Prodrugs" are designated
according to the invention as those derivatives of the compounds of
the general formula (I) which can be biologically less active or
even inactive themselves, but after administration are converted
under physiological conditions into the corresponding biologically
active form (for example meta-bolically, solvolytically or in
another manner).
[0075] Preferred compounds of the general formula (I) are those
[0076] in which
[0077] z represents O, S or CH.sub.2,
[0078] R.sup.1 and R.sup.2 are identical or different and represent
hydrogen, fluorine, chlorine, bromine, (C.sub.1-C.sub.4)-alkyl,
CF.sub.3, CHF.sub.2, CH.sub.2F, vinyl or
(C.sub.3-C.sub.5)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and is in the ortho position to
the bridge bond, in particular both substituents are unequal to
hydrogen and both are in the ortho position,
[0079] R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10,
[0080] in which
[0081] A represents O, S. NR.sup.11 or represents the group
--(CR.sup.12.dbd.CR.sup.13)--, in which
[0082] R.sup.11 denotes hydrogen or methyl, and R.sup.12 and
R.sup.13 are identical or different and denote hydrogen or
methoxy,
[0083] D represents a straight-chain (C.sub.1-C.sub.3)-alkylene
group which can be mono- or disubstituted, identically or
differently, by (C.sub.1-C.sub.4)-alkyl, hydroxyl, methoxy, ethoxy,
fluorine, chlorine, amino, mono-(C.sub.1-C.sub.4)-alkylamino or
mono-(C.sub.1-C.sub.4)-acylam- ino,
[0084] E represents a C(O) group,
[0085] L represents a C(O) or SO.sub.2 group,
[0086] G represents an NH group or represents a straight-chain
(C.sub.1-C.sub.3)-alkylene group, which can be mono- or
disubstituted, identically or differently, by methyl, ethyl,
hydroxyl, methoxy, fluorine, chlorine, amino, methylamino or
acetylamino,
[0087] m, n, o and p independently of one another in each case
represent the number 0 or 1, with the proviso that
[0088] in the case that L represents a C.dbd.O group, the sum
(m+n+o+p) is unequal to the number 0,
[0089] and
[0090] in the case that m and o in each case represent the number
1, A represents the radical NR.sup.11 and L represents a C.dbd.O
group, the sum (n+p) is unequal to the number 0,
[0091] and
[0092] R.sup.10 represents OR.sup.15, NR.sup.16R.sup.17,
(C.sub.3-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, naphth-yl,
phenyl, benzyl or represents a saturated, partly unsaturated or
aromatic 5- to 6-membered heterocycle having up to four identical
or different heteroatoms from the group consisting of N, O and/or
S, where the abovementioned radicals are optionally substituted by
one, two or three identical or different substituents selected from
the group consisting of halogen, hydroxyl, oxo, cyano, nitro,
amino, NR.sup.18R.sup.19, trifluoromethyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkoxy optionally substituted by R.sup.20,
(C.sub.3-C.sub.6)-cycloalkyl, --O--C(O)--R.sup.21,
--C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where
[0093] R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20,
R.sup.21, R.sup.22, R.sup.23, R.sup.24, R.sup.25, R.sup.26,
R.sup.27 and R.sup.28are identical or different and in each case
represent hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.6)-cycloalkyl, which for their part are optionally
mono- or polysubstituted, identically or differently, by halogen,
hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C4)-alkoxycarbonyl, (C.sub.1-C4)-alkoxy-carbonyl-amino,
(C.sub.1-C5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl,
[0094] or
[0095] R.sup.3 represents a group of the formula 4
[0096] R.sup.4 and R.sup.5 are identical or different and in each
case represent hydrogen, halogen or (C.sub.1-C.sub.4)-alkyl,
[0097] R6 represents hydrogen, halogen or a group of the
formula
-M.sup.a-R.sup.32,
[0098] in which
[0099] M represents a carbonyl group, a sulphonyl group or a
methylene group,
[0100] a represents the number 0 or 1,
[0101] and
[0102] R.sup.32 represents (C.sub.1-C.sub.10)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.2-C.sub.4)-alkenyl, naphth-yl,
phenyl, benzyl, pyridyl, pyridazinyl or pyridazinonyl, where the *
abovementioned radicals are optionally substituted by one, two or
three identical or different substituents selected from the group
consisting of halogen, hydroxyl, cyano, nitro, amino,
NR.sup.18R.sup.19, tri-fluoromethyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.3-C.sub.7)-cycloalkyl, phenyl,
which for its part is optionally substituted by halogen,
(C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-alkoxy- ,
trifluoromethyl, nitro or cyano, --O--C(O)--R.sup.21,
--C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where
[0103] R.sup.18, R.sup.19, R.sup.21, R.sup.22, R.sup.23, R.sup.24,
R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are identical or
different and in each case represent hydrogen, phenyl, benzyl,
(C.sub.1-C.sub.6)-alkyl or (C.sub.3-C.sub.6)-cycloalkyl, which for
their part are optionally mono- or polysubstituted, identically or
differently, by halogen, hydroxyl, amino, carboxyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxycarbonylamino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by halogen or hydroxyl,
[0104] R.sup.7 represents hydrogen,
[0105] and
[0106] R.sup.8 has the meaning of R.sup.6 indicated above and can
be identical to or different from this substituent,
[0107] and their pharmaceutically tolerable salts, solvates,
hydrates and hydrates of the salts.
[0108] Particularly preferred compounds of the general formula (I)
are those in which
[0109] Z represents O or CH.sub.2,
[0110] R.sup.1 and R.sup.2 are identical or different and represent
hydrogen, fluorine, chlorine, bromine, (C.sub.1-C.sub.4)-alkyl,
CF.sub.3, CHF.sub.2, CH.sub.2F, vinyl or
(C.sub.3-C.sub.5)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and in the ortho position to
the bridge bond, in particular both substituents are unequal to
hydrogen and both are in the ortho position,
[0111] R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10,
[0112] in which
[0113] A represents O, S or NH,
[0114] D represents a straight-chain (C.sub.1-C.sub.3)-alkylene
group, which can be mono- or disubstituted, identically or
differently, by methyl, ethyl, hydroxyl, methoxy, fluorine, amino
or acetylamino,
[0115] E represents a C(O) group,
[0116] L represents a C(O) or SO.sub.2 group,
[0117] G represents an NH group or represents a methylene
group,
[0118] m, n, o and p independently of one another in each case
represent the number 0 or 1, with the proviso that
[0119] in the case that L represents a C.dbd.O group, the sum
(m+n+o+p) is unequal to the number 0,
[0120] and
[0121] in the case that m and o in each case represent the number
1, A represents the radical NH and L represents a C.dbd.O group,
the sum (n+p) is unequal to the number 0,
[0122] and
[0123] R.sup.10 represents OR.sup.15, NR16R.sup.17,
(C.sub.1-C.sub.6)-alkyl, phenyl, benzyl or represents an aromatic
5- to 6-membered heterocycle having up to four identical or
different heteroatoms from the group consisting of N, O and/or S,
where the abovementioned radicals are optionally substituted by
one, two or three identical or different substituents selected from
the group consisting of fluorine, chlorine, hydroxyl, oxo, cyano,
nitro, amino, NR.sup.18R.sup.19, trifluoromethyl,
(C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-alkoxy optionally
substituted by R.sup.20, (C.sub.3-C.sub.6)-cycloalkyl,
--O--C(O)--R.sup.21, --C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where
[0124] R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20,
R.sup.21, R.sup.22, R.sup.23, R.sup.24, R.sup.25, R.sup.26,
R.sup.27 and R.sup.28 are identical or different and in each case
represent hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.6)-cycloalkyl, which for their part are optionally
mono- to disubstituted, identically or differently, by fluorine,
chlorine, hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxy-carbonylamino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by fluorine, chlorine or hydroxyl,
[0125] R.sup.4 and R.sup.5 are identical or different and in each
case represent hydrogen, fluorine, chlorine or methyl,
[0126] R.sup.6 represents hydrogen, halogen or a group of the
formula
-M.sub.a-R.sup.32,
[0127] in which
[0128] M represents a sulphonyl group or a methylene group,
[0129] a represents the number 0 or 1,
[0130] and
[0131] R.sup.32 represents (C.sub.1-C.sub.10)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, benzyl, pyridyl, pyridazinyl
or pyridazinonyl, where the abovementioned radicals are optionally
substituted by one or two identical or different substituents
selected from the group consisting of fluorine, chlorine, bromine,
hydroxyl, cyano, nitro, amino, NR.sup.18R.sup.19, trifluoromethyl,
(C.sub.1-C.sub.4)-alkyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.3-C.sub.7)-cycloalkyl, --O--C(O)--R.sup.21,
--C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where
[0132] R.sup.18, R.sup.19, R.sup.21, R.sup.22, R.sup.23, R.sup.24,
R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are identical or
different and in each case represent hydrogen, phenyl, benzyl,
(C.sub.1-C.sub.6)-alkyl or (C.sub.3-C.sub.6)-cycloalkyl, which for
their part are optionally mono- or disubstituted, identically or
differently, by fluorine, chlorine, hydroxyl, amino, carboxyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C4)-alkoxycarbonyl-amino, (C.sub.1-C.sub.5)-alkanoyloxy, a
heterocycle or phenyl which is optionally substituted by fluorine,
chlorine or hydroxyl,
[0133] R.sup.7 represents hydrogen,
[0134] R.sup.8 represents hydrogen, carboxyl,
(C.sub.1-C.sub.4)-alkoxycarb- onyl, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, benzyl, pyridyl,
phenylsulphonyl or benzylsulphonyl, where the abovementioned
radicals are optionally substituted by one or two identical or
different substituents selected from the group consisting of
fluorine, chlorine, bromine, hydroxyl, cyano, nitro, amino,
NR.sup.18R.sup.19, trifluoromethyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.3-C.sub.6)-cycloalkyl,
--O--C(O)--R.sup.21, --C(O)--OR.sup.22, --C(O)--NR.sup.23R.sup.24,
--SO.sub.2--NR.sup.25R.sup.26, --NH--C(O)--R.sup.27 and
--NH--C(O)--OR.sup.28, where
[0135] R.sup.18, R.sup.19, R.sup.21, R.sup.22, R.sup.23, R.sup.24,
R.sup.25, R.sup.26, R.sup.27 and R.sup.28 are identical or
different and in each case represent hydrogen, phenyl, benzyl,
(C.sub.1-C.sub.6)-alkyl or (C.sub.3-C.sub.6)-cycloalkyl, which for
their part are optionally mono- or polysubstituted, identically or
differently, by fluorine, chlorine, hydroxyl, amino, carboxyl,
(C.sub.1-C.sub.4)-alkoxy, (C.sub.1-C4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxycarbonylamino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl which is
optionally substituted by fluorine, chlorine or hydroxyl,
[0136] and their pharmaceutically tolerable salts, solvates,
hydrates and hydrates of the salts.
[0137] Very particularly preferred compounds of the general formula
(I) are those in which
[0138] Z represents O,
[0139] R.sup.1 and R.sup.2 are identical or different and represent
hydrogen, fluorine, chlorine, bromine, (C.sub.1-C.sub.4)-alkyl,
CF.sub.3, CHF.sub.2, CH.sub.2F, vinyl or
(C.sub.3-C.sub.5)-cycloalkyl, where at least one of the two
substituents is unequal to hydrogen and in the ortho position to
the bridge bond, in particular both substituents are unequal to
hydrogen and both are in the ortho position,
[0140] R.sup.3 represents a group of the formula
-A.sub.m-D.sub.n-E.sub.o-G.sub.p-L-R.sup.10,
[0141] in which
[0142] A represents O, S or NH,
[0143] D represents a methylene or ethylene group, which can be
mono- to disubstituted, identically or differently, by methyl,
ethyl, fluorine, amino or acetylamino,
[0144] E represents a C(O) group,
[0145] L represents a C(O) or SO.sub.2 group,
[0146] G represents an NH group or represents a methylene
group,
[0147] m, n, o and p independently of one another in each case
represent the number 0 or 1, with the proviso that
[0148] in the case that L represents a C.dbd.O group, the sum
(m+n+o+p) is unequal to the number 0,
[0149] and
[0150] in the case that m and o in each case represent the number
1, A represents the radical NH and L represents a C.dbd.O group,
the sum (n+p) is unequal to the number 0,
[0151] and
[0152] R.sup.10 represents OR.sup.15, NR.sup.16R.sup.17 or
represents (C.sub.1-C.sub.4)-alkyl, where R.sup.15, R.sup.16 and
R.sup.17 are identical or different and in each case represent
hydrogen, phenyl, benzyl, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.6)-cycloalkyl, which for their part are optionally
mono- to disubstituted, identically or differently, by fluorine,
chlorine, hydroxyl, amino, carboxyl, (C.sub.1-C.sub.4)-alkoxy,
(C.sub.1-C.sub.4)-alkoxycarbonyl,
(C.sub.1-C.sub.4)-alkoxycarbonylamino,
(C.sub.1-C.sub.5)-alkanoyloxy, a heterocycle or phenyl,
[0153] R.sup.4 and R.sup.5 are identical or different and in each
case represent hydrogen, fluorine, chlorine or methyl,
[0154] R.sup.6 represents hydrogen, halogen,
(C.sub.1-C.sub.10)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkylmethyl, phenyl, benzyl,
pyridazinonylmethyl, phenylsulphonyl or pyridylsulphonyl, where the
abovementioned aromatic radicals are optionally substituted by one
or two identical or different substituents selected from the group
consisting of fluorine, chlorine, cyano, nitro, trifluoromethyl,
methyl, methoxy, carboxyl or methoxycarbonyl,
[0155] R.sup.7 represents hydrogen,
[0156] R.sup.8 represents hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, benzyl, (10 phenylsulphonyl
or benzylsulphonyl, where the abovementioned aromatic radicals are
optionally substituted by one or two identical or different
substi-tuents selected from the group consisting of fluorine,
chlorine, cyano, trifluoromethyl, methyl or methoxy,
[0157] and their pharmaceutically tolerable salts, solvates,
hydrates and hydrates of the salts.
[0158] Compounds of the general formula (I) which are of particular
importance are those in which
[0159] Z represents CH.sub.2 or in particular represents
oxygen,
[0160] R.sup.1 and R.sup.2 are identical or different and represent
methyl, ethyl, propyl, isopropyl, chlorine, bromine, CF.sub.3,
vinyl or cyclopropyl , where both substituents are in the ortho
position to the bridge bond,
[0161] R.sup.4 and R.sup.5 independently of one another represent
methyl, fluorine or chlorine or in particular represent
hydrogen,
[0162] and
[0163] R.sup.7 represents hydrogen.
[0164] The abovementioned radical definitions which are general or
indicated in preferred ranges apply both to the final products of
the formula (I) and correspondingly to the starting substances or
intermediates needed in each case for preparation.
[0165] The radical definitions specifically indicated in the
respective combinations or preferred combinations of radicals are
arbitrarily also replaced, independently of the respective
combinations of the radicals indicated, by radical definitions of
other combinations.
[0166] Particularly preferred compounds of the formula (I) are
those in which Z represents oxygen.
[0167] Particularly preferred compounds of the formula (I) are
those in which R.sup.3 represents a group of the formula 5
[0168] which is located in the para position to the bridge bond and
in which R.sup.10 represents hydroxyl or the radical
--C(O)--R.sup.10 has the indicated meanings of R.sup.10 for a group
which, in the sense of a prodrug, can be broken down to the
carboxylic acid --C(O)--OH or its salts.
[0169] Particularly preferred compounds of the formula (I) are
those in which R.sup.4, R.sup.5 and R.sup.7 represent hydrogen.
[0170] Particularly preferred compounds of the formula (I) are
those in which R.sup.1 and R.sup.2 are both situated in the ortho
position to Z and represent bromine, trifluoromethyl, ethyl,
cyclopropyl and in particular represent methyl or chlorine.
[0171] Very particularly preferred compounds of the formula (Ia)
6
[0172] are those in which
[0173] R.sup.3 represents a group of the formula
--CH.sub.2--C(O)--OH, --CHF--C(O)--OH or --CF.sub.2--C(O)--OH,
[0174] and
[0175] R.sup.6 represents straight-chain or branched
(C.sub.1-C.sub.8)-alkyl.
[0176] Very particularly preferred compounds of the formula (Ib)
7
[0177] are likewise those in which
[0178] R.sup.1 and R.sup.2 are identical or different and represent
bromine, trifluoromethyl, ethyl, cyclopropyl and in particular
represent methyl or chlorine,
[0179] R.sup.3 represents a group of the formula
--NH--C(O)--CH.sub.2--C(O- )--R.sup.10, in which
[0180] R.sup.10 represents hydroxyl or the radical --C(O)--R.sup.10
has the meanings of R.sup.10 indicated above for a group, which in
the sense of a prodrug can be broken down to the carboxylic acid
--C(O)--OH or its salts,
[0181] and
[0182] R.sup.6 represents straight-chain or branched
(C.sub.1-C.sub.8)-alkyl.
[0183] The following individual compounds may be mentioned by way
of example and preferably:
[0184] Compounds of the formula 1 in which R.sup.3 has the meanings
indicated in Table 1 (*in the table denotes the linkage site):
1TABLE 1 1 8 R.sup.3 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
[0185] Individual compounds of the formula 2 in which R.sup.3 in
each case has the meanings indicated in Table 1 and R.sup.2,
instead of methyl from the formula 1, for each of the individual
compounds 1 to 35 in each case has the meanings indicated in Table
2 for R.sup.2:
2TABLE 2 2 44 R.sup.2 H I 45 46 F 47 48 CN Cl 49 50 Br 51 52
[0186] Individual compounds of the formula 3 in which R.sup.2 and
R.sup.3 in each case have the meanings indicated in Tables 1 and 2
and R.sup.1, instead of methyl from formula 2, for each of the
individual compounds 1 to 490 in each case has the meanings
indicated in Table 3 for R.sup.1:
3TABLE 3 3 53 R.sup.1 H I 54 55 F 56 57 CN Cl 58 59 Br 60 61
[0187] Individual compounds of the formula 4 in which R.sup.1,
R.sup.2 and R.sup.3 in each case have the I meanings indicated in
Tables 1, 2 and 3 and R.sup.6, instead of methyl from formula 3,
for each of the individual compounds 1 to 6860 in each case has the
meanings indicated in Table 4 for R.sup.6:
4TABLE 4 4 62 R.sup.6 H I 63 64 65 66 67 68 69 70 71 72 73 74 75 76
F 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 Cl 92 93 94 95 96 97
98 99 100 101 102 103 104 105 106 Br 107 108 109 110 111 112 113
114 115 116 117 118 119 120 121
[0188] The compounds of the general formula (I) according to the
invention can be prepared by reacting reactive indole derivatives
of the general formula (II) with reactive phenyl derivatives of the
general formula (III) 122
[0189] where the substituents R.sup.1, R.sup.2, R.sup.4, R.sup.5,
R.sup.6, R.sup.7 and R.sup.8 have the meanings indicated above,
and
[0190] R.sup.3' has the meaning indicated for R.sup.3 or represents
NO.sub.2, NH.sub.2, NH--PG, OH, O--PG, SH, S--PG, or represents an
aldehyde, cyano, carboxyl or (C.sub.1-C.sub.4)-alkoxy-carbonyl
group,
[0191] where PG represents a protective group,
[0192] X and Y in each case represent groups of opposite
reactivity, where, for example, X can be an electrophilic radical
which reacts with a nucleophilic Y substituent and vice versa,
[0193] Z' has the meaning indicated for Z or represents 123
[0194] if appropriate in the presence of inert solvents and
catalysts and if appropriate with isolation of the intermediates of
the general formula (IV) or directly to give compounds of the
formula (I).
[0195] Catalysts which may be mentioned by way of example are
coupling catalysts such as Pd, Rh and/or Cu compounds.
[0196] Examples of the reactive groups X and Y which may be
mentioned are: halogen, hydroxyl, CH.sub.2Br, mercapto, amino, CHO,
Li, magnesium, tin or boron derivatives.
[0197] The indoles of the general formula (II) which can be
employed according to the invention are known or can be prepared
according to known methods [compare, for example, Ozaki et al.,
Heterocycles 51, 727-731 (1999); Harvey et al., J. Chem. Soc., 473
(1959); Quadbeck et al., Hoppe-Seyler's Z. Physiolog. Chem. 297,
229 (1954); Chen et al., J. Org. Chem. 59, 3738 (1994); Synthesis,
480 (1988); J. prakt. Chem. 340, 608 (1998)].
[0198] The phenyl derivatives of the general formula (III) are
likewise known or can be prepared according to known methods
[compare, for example, van de Bunt, Recl. Trav. Chim. Pays-Bas 48,
131 (1929); Valkanas, J. Chem. Soc., 5554 (1963)].
[0199] The reaction of the starting compounds (II) with (III) in
general proceeds at normal pressure. However, it can also be
carried out at elevated or reduced pressure.
[0200] The reaction can be carried out in a temperature range from
-100.degree. C. to 200.degree. C., preferably between -78.degree.
C. and 150.degree. C., in the presence of inert solvents. Inert
solvents which may preferably be mentioned are: dimethylsulphoxide
(DMSO), dimethyl-formamide (DMF), N-methyl-2-pyrrolidinone (NMP),
tetrahydrofuran (THF), diethyl ether, dichloromethane etc.
Depending on the specific substituent pattern, in the reaction of
(II) and (III) intermediates of the formula (IV) can also be formed
in which, for example, the substituent R.sup.3' represents a nitro,
aldehyde, cyano, carboxyl or alkoxycarbonyl group or Z' represents
a CHOH or C(O) group, which are then further reacted with or
without isolation of these intermediates according to customary
methods to give compounds of the formula (I).
[0201] The process according to the invention can be illustrated by
way of example by the following reaction schemes: 124125
[0202] Depending on the meaning of the substituents R.sup.1,
R.sup.2, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, it can be
useful or necessary to vary these at individual process stages
within the scope of meaning indicated.
[0203] Protective groups (PG) are understood in the present
application as meaning those groups in starting materials,
intermediates and/or final products which protect functional groups
present such as, for example, carboxyl, amino, mercapto or hydroxyl
groups and which are customary in preparative organic chemistry.
The groups protected in this way can then be converted into free
functional groups in a simple manner under known conditions.
[0204] The compounds of the formula (I) according to the invention
show a surprising and valuable pharmacological spectrum of action
and can therefore be employed as versatile medicaments for the
treatment of human and mammals, as for example cats and dogs. In
particular, they can be employed in all indications which can be
treated using natural thyroid hormones, such as by way of example
and preferably, depression, goitre or cancer of the thyroid.
Preferably, using the compounds of the formula (I) according to the
invention, arteriosclerosis, hypercholesterolaemia, and
dyslipidaemia can be treated. Moreover, adiposity and obesity and
cardiac insufficiency can also be treated and a postprandial
lowering of the triglycerides can be achieved.
[0205] The compounds are also suitable for the treatment of certain
respiratory tract diseases, namely in particular of pulmonary
emphysema and for the medicinal promotion of maturation of the
lungs.
[0206] The compounds are furthermore suitable for the treatment of
painful conditions and migraine, for neuronal repair
(remyelinization) and also for the treatment of Alzheimer's
disease.
[0207] The compounds are furthermore suitable for the treatment of
osteoporosis, cardiac arrhythmias, hypothyroidism and skin
diseases.
[0208] Moreover, the compounds can also be employed for promotion
and regeneration of hair growth and for the treatment of
diabetes.
[0209] The active compounds according to the invention open up a
further treatment alternative and are an enrichment of pharmacy. In
comparison to the known and previously employed thyroid hormone
preparations, the compounds according to the invention show an
improved spectrum of action. They are preferably distinguished by
great specificity, good tolerability and lower side effects, in
particular in the cardiovascular area.
[0210] The efficacy of the compounds according to the invention can
be tested, for example, in vitro by the T3 promoter assay cell test
described below:
[0211] The test is carried out using a stably transfected, human
HepG2 hepatocarcinoma cell which expresses a luciferase gene under
the control of a thyroid hormone-regulated promoter. The vector
used for the transfection carries, ahead of the luciferase gene, a
minimal thymidine kinase promoter having a thyroid
hormone-responsive element (TRE), which consists of two inverted
palindromes of 12 Bp each and an 8 Bp spacer.
[0212] For the test, the cell cultures are inoculated into 96 well
plates in Eagle's Minimal Essential Medium with the following
additives: glutamine, tricine
[N-(tris(hydroxy-methyl)methyl)glycine], sodium pyruvate,
non-essential amino acids (L-Ala, L-Asn, L-Asp, L-Pro, L-Ser,
L-Glu, Gly), insulin, selenium and transferrin. The cultures are
grown for 48 hours at 37.degree. C. and under a 10% CO.sub.2
atmosphere. Serial dilutions of test substance or reference
compound (T3, T4) and costimulator retinolic acid are then added to
the test cultures and these are incubated as beforehand for a
further 48 or 72 hours. Each substance concentration is tested in
four replicates. For the determination of the luciferase induced by
T3 or other substances, the cells are then lysed by addition of a
Triton- and luciferin-containing buffer (from Promega) and
immediately measured luminometrically. The EC.sub.50 values of each
compound are calculated. Representative results for the compounds
according to the invention are shown in Table 5:
5 TABLE 5 Example No. EC.sub.50 [nM] 5 22 6 8 11 0.5 15 4 16 21
[0213] The compounds according to the invention also show
surprisingly advantageous properties in the tests described
below:
[0214] Test descriptions for the discovery of pharmacologically
active substances:
[0215] The substances which are to be investigated for their serum
cholesterol-lowering action in vivo are administered orally to male
mice having a bodyweight of between 25 and 35 g. The animals are
divided into groups having an identical number of animals, as a
rule n=7-10, one day before the start of the experiment. During the
entire experiment, drinking water and feed is available ad libitum
to the animals. The substances are administered orally once daily
for 7 days. For this purpose, the test substances are dissolved,
for example, in a solution of Solutol HS 15+ethanol+sodium chloride
solution (0.9%) in a ratio 1+1+8 or in a solution of Solutol HS
15+sodium chloride solution (0.9%) in the ratio 2+8. The dissolved
substances are administered in a volume of 10 ml/kg of bodyweight
using a stomach tube. As a control group, animals are used which
have been treated exactly the same, but only receive the solvent
(10 ml/kg of bodyweight) without test substance.
[0216] Before the first substance administration, blood is taken
from each mouse for the determination of the serum cholesterol by
puncture of the retroorbital venous plexus (preliminary value). The
test substance is then administered to the animals for the first
time using a stomach tube. 24 hours after the last substance
administration (on the 8th day after the start of treatment), blood
is again taken from each animal for the determination of the serum
cholesterol by puncture of the retroorbital venous plexus. The
blood samples are centrifuged and, after recovering the serum, the
cholesterol is determined photometrically using an EPOS analyser
5050 (Eppendorf-Gertebau, Netheler & Hinz GmbH, Hamburg). The
determination is carried out using a commercially available enzyme
test (Boehringer Mannheim, Mannheim).
[0217] The action of the test substances on the serum cholesterol
concentration is determined by subtraction of the cholesterol value
of the 1st blood sample (preliminary value) from the cholesterol
value of the 2nd blood sample (after treatment). The differences of
all cholesterol values of a group are averaged and compared with
the average value of the differences of the control group.
[0218] Statistical analysis is carried out using Student's t test
after prior checking of the variances for homogeneity.
[0219] Substances which statistically significantly (p<0.05)
lower the serum cholesterol of the treated animals, compared with
the control group, by at least 10% are regarded as
pharmacologically active.
[0220] At the end of the test, the animals are weighed and
sacrificed after taking blood. To check for potential
cardiovascular side effects under the influence of substance, the
hearts are removed and weighed. An effect on the cardiovascular
system can be. detected by a significant increase in the heart
weight. A further parameter which can be used for the substance
action is a bodyweight change.
[0221] In an analogous manner, it is possible to use, for example,
NMRI mice, ob,ob mice, Wistar rats or fa,fa diabetic rats as
experimental animals for this test.
[0222] A further in vivo test in which the compounds according to
the invention show surprisingly advantageous properties is the
cholesterol-fed rat animal model [A. Taylor et al., Molecular
Pharmacology 52, 542-547 (1997); Z. Stephan et al., Atherosclerosis
126, 53-63 (1996)].
[0223] Furthermore, the cholesterol-lowering action of the
compounds according to the invention can also be checked on
normocholesterolaemic dogs by oral administration of the test
substances for 5-7 days.
[0224] For the further investigation of potential cardiovascular
side effects under the influence of substance, it is possible to
use, inter alia, the determination of the expression of the mRNA of
the "HCN2" ion channel ("hyperpolarization-activated cyclic
nucleotide-gated channel") in mouse or rat hearts [cf. also: Trost
et al., Endocrinology 141 (9), 3057-3064 (2000); Gloss et al.,
Endocrinology 142 (2), 544-550 (2001); Pachuki et al., Circulation
Research 85, 498-503 (1999)]:
[0225] HCN2 Assay
[0226] The quantification of the mRNA of the
"hyperpolarization-activated cyclic nucleotide-gated" cation
channel (HCN2) in rat hearts was carried out by means of real-time
PCR (TaqMan-PCR; Heid et al., Genome Res. 6 (10), 986-994). For
this, after preparation of the hearts the total RNA is isolated by
means of RNaesy columns (from Qiagen), digested with DNase and then
transcribed into cDNA (SUPERSCRIPT-II RT cDNA synthesis kit, from
Gibco). The HCN2 mRNA determination is carried out on an ABI Prism
7700 apparatus (from Applied Biosystems). The sequence of the
"forward" and "reverse" primer read: 5'-GGGAATCGACTCCGAGGTC-3' or
5'-GATCTTGGTGAAACGCACGA-3', that of the fluorescent probe
5'-6FAM-ACAAGACGGCCCGTGCACTACGC-TAMRA-3 (FAM=fluorescent dye
6-carboxyfluorescein; TAMRA=quencher
6-carboxytetramethylrhodamine). During the polymerase chain
reaction, the Taq polymerase of the fluorescent dye FAM is removed
by the 5' exonuclease activity and the previously quenched
fluorescence signal is thereby obtained. The "threshold cycle" (Ct
value) is distinguished as the number of cycles in which the
fluorescence intensity was 10 standard deviations above the
background fluorescence. The relative expression of the HCN2 mRNA
calculated thereby is then standardized to the expression of the
ribosomal protein L32.
[0227] In an analogous manner, this assay can also be carried out
using mice hearts. The sequence of the "forward" and "reverse"
primer in this case read 5'-CGAGGTGCTGGAGGAATACC-3' or
5'-CTAGCCGGTCAATAGCCACAG-3', that of the fluorescent sample
5'-6FAM-CATGATGCGGCGTGCCTTTGAG-TAMRA-3.
[0228] All customary administration forms are suitable for the
administration of the compounds of the general formula (I), i.e.
oral, parenteral, inhalatory, nasal, sublingual, buccal, rectal or
external such as, for example, transdermal, in particular
preferably oral or parenteral. In the case of parenteral
administration, intravenous, intramuscular or subcutaneous
administration may be mentioned in particular, e.g. as a
subcutaneous depot. Oral administration is very particularly
preferred.
[0229] In particular, compounds of the general formulae (Ia) and
(Ib) have surprisingly advantageous pharmacokinetic properties
after oral administration, for example with respect to
bioavailability, the active compound concentration in the blood,
the half-life and/or the excretion rate.
[0230] The active compounds can be administered here on their own
or in the form of preparations. For oral administration, suitable
preparations are, inter alia, tablets, capsules, pellets, coated
tablets, pills, granules, solid and liquid aerosols, syrups,
emulsions, suspensions and solutions. The active compound must be
present here in such an amount that a therapeutic action is
achieved. In general, the active compound can be present in a
concentration of 0.1 to 100% by weight, in particular 0.5 to 90% by
weight, preferably 5 to 80% by weight. In particular, the
concentration of the active compound should be 0.5-90% by weight,
i.e. the active compound should be present in amounts which are
sufficient to achieve the dosage range indicated.
[0231] For this purpose, the active compounds can be converted into
the customary preparations in a known manner. This is carried out
using inert, non-toxic, pharmaceutically suitable vehicles,
excipients, solvents, vehicles, emulsifiers and/or dispersants.
[0232] Excipients which may be mentioned are, for example: water,
non-toxic organic solvents such as, for example, paraffins,
vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol,
glycerol), glycols (e.g. polyethylene glycol), solid carriers such
as ground natural or synthetic minerals (e.g. talc or silicates),
sugars (e.g. lactose), emulsifiers, dispersants (e.g.
polyvinylpyrrolidone) and lubricants (e.g. magnesium sulphate).
[0233] In the case of oral administration, tablets can, of course,
also contain additives such as sodium citrate together with
additional substances such as starch, gelatin and the like. Aqueous
preparations for oral administrations can furthermore be mixed with
flavour enhancers or colorants.
[0234] In the case of oral administration, doses of 0.001 to 5
mg/kg, preferably 0.001 to 3 mg/kg, of bodyweight are preferably
administered every 24 hours.
[0235] The new active compounds can be administered on their own
and, if required, also in combination with other active compounds,
preferably from the group consisting of CETP inhibitors,
antidiabetics, antioxidants, cytostatics, calcium antagonists,
hypotensive agents, thyroid hormones, inhibitors of HMG-CoA
reductase, inhibitors of HMG-CoA reductase gene expression,
squalene synthesis inhibitors, ACAT inhibitors,
circulation-promoting agents, platelet aggregation inhibitors,
anticoagulants, angiotensin II receptor antagonists, cholesterol
absorption inhibitors, MTP inhibitors, aldose reductase inhibitors,
fibrates, niacin, anorectics, lipase inhibitors and PPAR
agonists.
[0236] The following working examples are intended to illustrate
the invention by way of example without restrictive action on the
scope of protection.
6 Abbreviations used TLC Thin-layer chromatography DCI Direct
chemical ionization (in MS) DMF N,N-Dimethylformamide DMSO Dimethyl
sulphoxide EI Electron impact ionization (in MS) HPLC
High-pressure, high-performance liquid chromatography conc.
concentrated MS Mass spectroscopy NMP N-Methylpyrrolidinone NMR
Nuclear magnetic resonance spectroscopy R.sub.f Retention index (in
TLC) R.sub.t Retention time (in HPLC) THF Tetrahydrofuran aq.
aqueous dec. decomposition
[0237] Starting Compounds
EXAMPLE I
5-(2,6-Dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole
[0238] 126
[0239] 5 g of 5-hydroxy-3-isopropylindole are dissolved in 10 ml of
THF and treated with 3.2 g of potassium tert-butoxide. The reaction
mixture is stirred for 20 minutes at room temperature and the
solvent is removed in vacuo. The phenoxide is dissolved in 10 ml of
DMF and added dropwise to 6.46 g of 1,2,6-trichloro-4-nitrobenzene
in 10 ml of DMF at 0.degree. C. The reaction mixture is stirred for
30 minutes at 0.degree. C. and slowly allowed to warm to room
temperature. The reaction mixture is poured onto water, extracted
with ethyl acetate, dried over sodium sulphate and the solvent is
removed in vacuo. Chromatographic purification (cyclohexane/ethyl
acetate) affords 663 mg of
5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole.
[0240] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.30, d, 6H;
3.09, sept., 1H; 6.79, dd, 1H; 6.99, m, 2H; 7.31, s, 1H; 7.89, s,
broad, 1H; 8.32, s, 2H.
EXAMPLE II
5-(2-Chloro-6-methyl-4-nitrophenoxy)-3-isopropyl-1H-indole
[0241] 127
[0242] 4.4 g of 5-hydroxy-3-isopropylindole are dissolved in 10 ml
of THF and treated at room temperature with 2.82 g of potassium
tert-butoxide. The mixture is stirred for 30 minutes at room
temperature and concentrated in a rotary evaporator. The phenoxide
is dissolved in DMF, treated at 0.degree. C. with 5.17 g of
1,2-dichloro-4-nitro-5-methylbenze- ne and stirred for 30 minutes
at 0.degree. C. The mixture is stirred for 15 minutes at room
temperature and subsequently 1 hour at 50.degree. C. The reaction
mixture is allowed to cool, poured onto water, extracted twice with
ether and the combined organic phases are washed twice with water.
The aqueous phases are extracted with dichloromethane, the combined
organic phases are concentrated in a rotary evaporator and the
residue is purified chromatographically (cyclohexane/ethyl
acetate). 6.65 g of
5-(2-chloro-6-methyl-4-nitrophenoxy)-3-isopropyl-1H-indole are
obtained.
[0243] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
2.31, s, 3H; 3.07, sept., 1H; 6.75, dd, 1H; 6.92, m, 1H; 6.99, m,
1H; 7.29, s, 1H; 7.87, s, broad, 1H.
EXAMPLE III
3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylaniline
[0244] 128
[0245] 500 mg of
5-(2-chloro-6-methyl-4-nitrophenoxy)-3-isopropyl-1H-indol- e
(Example II) are suspended in 10 ml of ethanol and hydrogenated
with 50 mg of palladium on active carbon (10%) at atmospheric
pressure for 2 hours. The mixture is filtered through kieselguhr,
the solvent is removed in vacuo and the product is purified by
chromatography (cyclohexane/ethyl acetate). 271 mg of
3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methyla- niline are
obtained.
[0246] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29, d, 6H;
2.11, s, 3H; 3.07, sept., 1H; 3.61, s, broad, 2H; 6.50, dd, 1H;
6.66, dd, 1H; 6.78, dd, 1H; 6.94, d, 2H; 7.20, s, 1H; 7.25, m, 1H;
7.78, s, broad, 1H.
EXAMPLE IV
3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]aniline
[0247] 129
[0248] 500 mg of
5-(2,6-dichloro-4-nitrophenoxy)-3-isopropyl-1H-indole (Example I)
are stirred with 6.18 g of tin(II) chloride dihydrate in 5 ml of
NMP for 17 hours at 50.degree. C. The solvent is removed in vacuo
and the residue is taken up in ethyl acetate. The mixture is washed
with saturated ammonium chloride solution and saturated sodium
chloride solution, the organic phase is dried and the solvent is
removed in vacuo. The product is precipitated with diethyl ether.
By chromatographic purification (cyclohexane/ethyl acetate) of the
solid, 174 mg of
3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]aniline are
obtained.
[0249] .sup.1H-NMR (300 MHz, DMSO-d.sub.6):.delta.=1.21, d, 6H;
2.95, sept., 1H; 5.56, s, 2H; 6:63, dd, 1H; 6.71, s, 2H; 6.75, m,
1H; 7.06, d, 1H; 7.24, d, 1H.
EXAMPLE V
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzaldehyde
[0250] 130
[0251] 12.8 g (70.27 mmol) of 5-hydroxy-3-isopropyl-indole are
dissolved in 275.8 ml of DMSO, 10.68 g (77.3 mmol) of potassium
carbonate are introduced in solid form, the mixture is stirred for
10 minutes at room temperature and afterwards 19.43 g (70.27 mmol)
of 3,5-bistrifluoromethyl-4-chlorobenzaldehyde are introduced in
portions. After stirring at 50.degree. C. for 3 hours the batch is
poured onto a mixture of 400 ml of ethyl acetate and 250 ml of
saturated ammonium chloride solution. After phase separation, the
aqueous phase is extracted again with ethyl acetate, and the
combined organic phases are washed twice with sodium chloride
solution and dried over sodium sulphate. After removing the drying
agent and distilling off the solvent the crude product is
chromatographed on silica gel 60 (Merck 0.040-0.063 mm) using
toluene.
[0252] Yield: 18.55 g (56.6%)
[0253] MS (DCI): 450 ([M+NH.sub.3+NH.sub.4]+, 100%)
[0254] R.sub.f: 0.5 (toluene:ethyl acetate=8:2)
[0255] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.25, d, 6H;
3.04, quin, 1H; 6.73, dd, 1H; 6.87, d, 1H; 6.96, d, 1H; 7.22, d,
1H; 7.85, broad s, 1H; 8.45, s, 2H; 10.11, s, 1H.
EXAMPLE VI
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzyl
alcohol
[0256] 131
[0257] 0.27 g (7.22 mmol) of sodium borohydride is added to a
solution of 1.0 g (2.41 mmol) of aldehyde derivative from Example V
in 20 ml of methanol in 4 portions at room temperature and the
mixture is stirred for 1 hour. Afterwards the reaction solution is
concentrated to one half, 60 ml of water are added and the mixture
is concentrated until methanol is completely evaporated in a rotary
evaporator. The aqueous phase is extracted three times with ethyl
acetate, the combined organic phases are washed with sodium
chloride solution, dried and concentrated, and the residue is dried
in a high vacuum.
[0258] Yield: 0.996 g (96.8%)
[0259] MS (ESI): 418 ([M+H].sup.+, 35%)
[0260] HPLC: R.sub.t=4.97 (97.7%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/minute; 210
nm
[0261] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
1.96, t, 1H; 3.04, quin, 1H; 4.87, d, 2H; 6.72, dd, 1H; 6.85, d,
1H; 6.93, d, 1H; 7.2, d, 1H; 7.78, broad s, 1H; 7.94, s, 2H.
EXAMPLE VII
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzyl
bromide
[0262] 132
[0263] 1.273 g (3.02 mmol) of triphenylphosphine dibromide are
added under argon in portions at 0.degree. C. to a solution of 0.97
g (2.32 mmol) of benzyl alcohol derivative from Example VI in 15 ml
of acetonitrile and 0.3 ml (3.72 mmol) of pyridine. After 15
minutes the cooling bath is removed and the mixture is stirred for
2 hours at room temperature. The reaction solution is concentrated
in vacuo, and the residue is dissolved in a little toluene and
purified by chromatography on silica gel 60 by means of
toluene.
[0264] Yield: 611 mg(54.7%)
[0265] MS (EI): 481 ([M].sup.+, 60%)
[0266] HPLC: R.sub.t=5.30 (80.7%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/minute; 210
nm
[0267] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
3.06, quin, 1H; 4.56, s, 2H; 6.70, dd 1H; 6.88, d, 1H; 6.95, d, 1H;
7.23, d, 1H; 7.8, broad s, 1H; 8.0, s, 2H.
EXAMPLE VIII
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-phenylacetonitril-
e
[0268] 133
[0269] 72.9 mg (1.49 mmol) of sodium cyanide are added at
50.degree. C. to a solution of 0.57 g (1.19 mmol) of benzyl bromide
from Example VII in 3.5 ml of dimethylformamide and 0.38 ml of
water and the mixture is stirred for 60 minutes at 50.degree. C.
Dimethyl-fornamide is subsequently distilled off, the concentrate
is diluted with ethyl acetate and water, and the aqueous phase is
separated off and extracted again with ethyl acetate. The combined
organic phases are washed with sodium chloride solution, dried over
sodium sulphate, filtered and concentrated. The purification of the
crude product is carried out on silica gel 60 by means of
toluene/ethyl acetate (toluene, toluene/ethyl acetate=18:1 and
18:1.5).
[0270] Yield: 374 mg (73.9%)
[0271] MS (EI): 426 ([M].sup.+, 60%)
[0272] R.sub.f: 0.51 (toluene:ethyl acetate=9:1)
[0273] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
3.06, quin, 1H; 3.93, s, 2H; 6.72, d 1H; 6.84, d, 1H; 6.96, d, 1H;
7.23, d, 1H; 7.82, broad s, 1H; 7.9, s, 2H.
EXAMPLE IX
tert-Butyl (4-hydroxy-3,5-dimethylphenoxy)acetate
[0274] 134
[0275] 10 g of dimethylhydroquinone are dissolved in 750 ml of a
mixture of 40% DMF and 60% THF and treated with 117 g of caesium
carbonate. 14.1 g of tert-butyl bromoacetate are added dropwise at
-25.degree. C. and the reaction mixture is stirred for 17 hours at
room temperature. After addition of 10 g of potassium carbonate the
reaction mixture is stirred for 24 hours at room temperature,
poured onto water and extracted twice with ethyl acetate. The
combined organic phases are washed with NaCl solution, dried over
sodium sulphate and the solvent is removed in vacuo. By
chromatographic purification (cyclohexane/ethyl acetate) 1.27 g of
tert-butyl (4-hydroxy-3,5-dimethylphenoxy)acetate are obtained.
[0276] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.42, s, 9H;
2.11, s, 6H; 4.47, s, 2H; 6.48, s, 2H; 7.74, s, 1H.
EXAMPLE X
5-Bromo-3-isopropyl-1H-indole
[0277] 135
[0278] 10 g of bromophenylhydrazine hydrochloride are suspended in
50 ml of acetic acid and treated dropwise at 80.degree. C. with
3.85 g of 3-methylbutyraldehyde. The reaction mixture is stirred
for 3 hours at reflux, allowed to cool and the solvent is removed
in vacuo. The residue is taken up in ethyl acetate, extracted with
water, the aqueous phase is extracted with ethyl acetate, the
combined organic phases are washed with water and sodium carbonate
solution, dried over sodium sulphate and the solvent is removed in
vacuo. Chromatographic purification (cyclohexane/ethyl acetate)
affords 8.6 g of 5-bromo-3-isopropyl-1H-indol- e.
[0279] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.35, d, 6H;
3.15, sept., 1H; 6.96, d, 1H; 7.24, m, 2H; 7.77, d, 1H; 7.89, s,
broad, 1H.
EXAMPLE XI
5-Bromo-1-[tert-butyl(dimethyl)silyl]-3-isopropyl-1H-indole
[0280] 136
[0281] 0.50 g (12.6 mmol) of 60% strength sodium hydride in
paraffin oil is introduced under argon into 20 ml of THF at room
temperature. A solution of 2.0 g (8.40.mmol) of
5-bromo-3-isopropyl-1H-indole (Example X) in 20 ml of THF is added
dropwise and the mixture is stirred until evolution of gas can no
longer be detected. 2.03 g (13.44 mmol) of
tert-butyl(chloro)dimethylsilane are subsequently added dropwise.
After a short reaction time a precipitate deposits. The batch is
stirred for 3 h at room temperature. It is treated with 200 ml of
water. The aqueous phase is extracted twice with ethyl acetate, and
the combined org. phases are dried and concentrated in a rotary
evaporator. The residue is chromatographed on silica gel (eluent:
cyclohexane). 2.63 g (89%) of
5-bromo-1-[tert-butyl(dimethyl)silyl]-3-isopropyl-1H-indole are
obtained.
[0282] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=0.58, s, 6H;
0.89, s, 9H; 1.33, d, 6H; 3.12, sept., 1H; 6.88, s, 1H; 7.20, dd,
1H; 7.32, d, 1H; 7.71, d, 1H.
EXAMPLE XII
1-[tert-Butyl(dimethyl)silyl]-3-isopropyl-1H-indol-5-yl-boronic
acid
[0283] 137
[0284] 1.30 g (3.69 mmol) of
5-bromo-l-[tert-butyl(dimethyl)silyl]-3-isopr- opyl-1H-indole
(Example XI) dissolved under argon in 10 ml of THF are introduced
at -78.degree. C. 2.50 ml (4.24 mmol) of a 1.6 N tert-butyllithium
solution in n-hexane are added dropwise. The mixture is stirred for
30 min at -78.degree. C. 1.70 ml (7.38 mmol) of triiso-propyl
borate are subsequently added dropwise. The batch is stirred for 2
h at -78.degree. C.
[0285] It is subsequently treated with 4 ml of water. The aqueous
phase is extracted three times with diethyl ether, and the combined
org. phases are dried and concentrated in a rotary evaporator. The
residue is purified chromatographically (eluent:cyclo-hexane,
cyclohexane/ethyl acetate 5:1, 3:1). 0.68 g (58%) of
1-[tert-butyl(dimethyl)-silyl]-3-isopr- opyl-1H-indol-5-yl-boronic
acid is obtained.
[0286] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=0.65, s, 6H;
0.93, s, 9H; 1.48, d, 6H; 3.37, sept., 1H; 6.93, s, 1H; 7.62, d,
1H; 8.08, d, 1H; 8.64, s, 1H. MS (ESI): 318 (M+H).
EXAMPLE XIII
tert-Butyl
[4-({1-[tert-butyl(dimethyl)silyl]-3-isopropyl-1H-indol-5-yl}ox-
y)-3,5-di-methylphenoxy]acetate
[0287] 138
[0288] 0.50 g (1.58 mmol) of
1-[tert-butyl(dimethyl)silyl]-3-isopropyl-1H-- indol-5-yl-boronic
acid (Example XII), 0.437 g (173 mmol) of
tert-butyl-(4-hydroxy-3,5-dimethylphenoxy)acetate (Example IX),
0.286 g (1.58 mmol) of copper(II) acetate and 0.50 g of molecular
sieve (4 .ANG., powdered) are suspended in 10 ml of dried
dichloromethane. 0.64 ml (7.88 mmol) of pyridine and 1.10 ml (7.88
mmol) of triethylamine are added dropwise at room temperature. The
batch is stirred overnight at room temperature. The batch is
subsequently filtered through silica gel and washed with
dichloromethane. The filtrate is concentrated and the residue is
filtered through silica gel (dichloromethane). 0.525 g (62%) of
tert-butyl-[4-({1-[tert-butyl-(dimethyl)silyl]-3-isopropyl-1H-indol-5-yl}-
oxy)-3,5-dimethylphenoxy]acetate is obtained.
[0289] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=0.54, s, 6H;
0.89, s, 9H; 1.27, d, 6H; 1.50, s, 9H; 2.12, s, 6H; 3.01, sept.,
1H; 4.50, s, 2H; 6.63, s, 3H; 6.83, dd, 2H; 7.29, d, 1H.
EXAMPLE XIV
3-Isopropyl-5-(4-nitro-2,6-dimethyl-phenoxy)-1H-indole
[0290] 139
[0291] 11.44 g (58.76 mmol) of 5-hydroxy-3-isopropyl-indole are
dissolved in 350 ml of DMSO, 8.93 g (64.63 mmol) of potassium
carbonate in solid form are introduced and subsequently 9.94 g
(58.76 mmol) of 3,5-dimethyl-4-fluoronitrobenzene are added. The
reaction solution is stirred for 2 hours at 100.degree. C. under
argon. Afterwards it is cooled to room temperature, 100 ml of ethyl
acetate and 600 ml of H.sub.2O are added; ethyl acetate is
separated off after phase separation and the aqueous phase is
re-extracted twice with ethyl acetate. The combined organic phases
are washed twice with sodium chloride solution, dried over sodium
sulphate, filtered and concentrated to dryness. The residue is
purified by chromatography on silica gel by means of
cyclohexane/ethyl acetate (10:1).
[0292] Yield: 11.96 g (62.8%)
[0293] MS (DCI): 342 ([M+NH.sub.4].sup.+, 100%)
[0294] R.sub.f: 0.26 (cyclohexane:ethyl acetate=8:2)
[0295] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28 (d, 6H);
2.24 (s, 6H); 3.05 (quin, 1H); 6.72 (dd, 1H); 6.84 (d, 1H); 6.99
(d, 1H); 7.27 (d, 1H); 7.87 (s, 1H); 8.03 (s, 2H).
EXAMPLE XV
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dimethyl-phenylamine
[0296] 140
[0297] 11.95 g (36.85 mmol) of nitro compound from Example XIV are
hydrogenated in 500 ml of methanol/ethanol mixture using 550 mg of
palladium/active carbon (10%) at 3 bar. The mixture is filtered
through kieselguhr, the solvent is removed in vacuo and the product
is purified by chromatography (toluene/ethyl acetate).
[0298] Yield: 10.75 g (97.9%)
[0299] MS (DCI): 295 ([M+H].sup.+, 100%)
[0300] R.sub.f: 0.36 (toluene:ethyl acetate=9:1)
[0301] HPLC: R.sub.t=4.15 (98.9%) 0,5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
EXAMPLE XVI
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dichloro-benzaldehyde
[0302] 141
[0303] Analogously to the procedure of Example V, 10.0 g (57.07
mmol) of 5-hydroxy-3-isopropylindole are dissolved in 300 ml of
DMSO, 8.68 g (62.77 mmol) of potassium carbonate are added, the
mixture is stirred for 10 min at room temperature and 11.95 g
(57.07 mmol) of 4,5,6-trichlorobenzaldehyde are introduced in
portions, and the mixture is additionally stirred for 2 hours at
room temperature and 2 hours at 50.degree. C. After quenching with
ethyl acetate/ammonium chloride solution and silica gel
chromatography by means of toluene, 12.01 g (85.4%) of the desired
product are obtained.
[0304] MS (C.sub.1-POS): 348 ([M+H].sup.+, 100%)
[0305] R.sub.f: 0.60 (toluene:ethyl acetate 9:1)
[0306] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29 (d, 6H);
3.08 (quin, 1H); 6.78 (dd, 1H); 6.99 (dd, 2H); 7.27 (d, 1H); 7.85
(broad s, 1H); 7.92 (s, 2H); 9.95 (s, 1H).
EXAMPLE XVII
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dichlorobenzyl alcohol
[0307] 142
[0308] Preparation is carried out in analogy to the procedure of
Example VI from 5.0 g (12.2 mmol) of aldehyde derivative from
Example XVI by means of 1.39 g (36.61 mmol) of sodium
borohydride.
[0309] Yield: 4.62 g (100%)
[0310] MS (CI-POS):350 ([M+H].sup.+, 100%)
[0311] R.sub.f: 0.16 (toluene:ethyl acetate 9:1)
[0312] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29 (d, 6H);
1.83 (weak t, 1H); 3.08 (quin, 1H); 4.71 (d, 2H); 6.8 (dd, 1H);
6.95 (d, 1H); 6.99 (d, 1H); 7.23 (d, 1H); 7.42 (s, 2H); 7.82 (broad
s, 1H).
EXAMPLE XVIII
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dichlorobenzyl bromide
[0313] 143
[0314] Analogously to the procedure of Example VII, 4.8 g (12.66
mmol) of benzyl alcohol derivative from Example XVII are reacted
with 6.95 g (16.46 mmol) of dibromo-triphenylphosphorane and 1.6 g
(20.26 mmol) of pyridine in 80 ml of acetonitrile.
[0315] Yield: 2.03 g (35.5%)
[0316] MS (CI-POS):413 ([M+H].sup.+, 57%)
[0317] HPLC: R.sub.t=5.62 (91.4%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0318] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.3 (d, 6H); 3.1
(quin, 1H); 4.43 (s, 2H); 6.77 (dd, 1H); 6.97 (s, 1H); 7.02 (d,
1H); 7.24 (d, 1H); 7.43 (s, 2H); 7.82 (broad s, 1H).
EXAMPLE XIX
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dichlorophenylacetonitrile
[0319] 144
[0320] Analogously to the procedure of Example VIII, 1.0 g (2.42
mmol) of benzyl bromide from Example XVIII is reacted with 0.15 g
(3.03 mmol) of sodium cyanide in DMF/H.sub.2O (10:1) at 50.degree.
C. in 60 min. After isolation of the crude product (distilling off
DMF and quenching with ethyl acetate/water), chromatography is
carried out on silica gel 60 by means of toluene.
[0321] Yield: 0.763 g (65.4%)
[0322] MS (DCI): 359 ([M+H].sup.+, 67%)
[0323] R.sub.f: 0.47 (toluene:ethyl acetate=9:1)
[0324] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.3 (d, 6H); 3.09
(quin, 1H); 3.78 (s, 2H); 6.78 (dd, 1H); 6.97 (d, 2H); 7.25 (d,
1H); 7.4 (s, 2H); 7.85 (broad s, 1H).
EXAMPLE XX
4-(3-Cyclohexylmethyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzaldehy-
de
[0325] 145
[0326] Analogously to the procedure of Example V, 2.0 g (8.72 mmol)
of 5-hydroxy-3-cyclohexylmethyl-indole are dissolved in 50 ml of
DMSO, 1.33 g (9.59 mmol) of potassium carbonate are added, the
mixture is stirred for 10 min at room temperature and afterwards
2.41 g (8.72 mmol) of 3,5-bis-trifluoromethyl-4-chlorobenzaldehyde
are introduced in portions. After stirring overnight at 50.degree.
C., the batch is worked up analogously to Example V and the crude
product is chromatographed on silica gel 60 by means of
toluene.
[0327] Yield: 2.23 g (49.8%)
[0328] MS (DCI): 504 ([M+NH.sub.3+NH.sub.4].sup.+, 100%)
[0329] R.sub.f: 0.57 (toluene:ethyl acetate=9:1)
[0330] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=0.91 (m, 2H);
1.15 (m, 4H); 1.5 (m, 1H); 1.66 (m, 4H); 2.5 (d, 2H); 6.71 (dd,
1H); 6.82 (d, 1H); 6.97 (d, 1H); 7.22 (d, 1H); 7.89 (broad s, 1H);
8.46 (s, 2H); 10.11 (s, 1H).
EXAMPLE XXI
4-(3-Cyclohexylmethyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzyl
alcohol
[0331] 146
[0332] Preparation is carried out in analogy to the procedure of
Example VI from 2.20 g (4.29 mmol) of aldehyde derivative from
Example XX with 0.49 g (12.86 mmol) of sodium borohydride.
[0333] Yield: 2.05 g (100%)
[0334] MS (ESI): 4.72 ([M+H].sup.+, 100%)
[0335] HPLC: R.sub.t=5.34 (98,4%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0336] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=0.9 (m, 2H); 1.13
(m, 4H); 1.5 (m, 1H); 1.63 (m, 4H); 1.95 (t, 1H); 2.5 (d, 2H); 4.88
(d, 2H); 6.7 (dd, 1H); 6.81 (d, 1H); 6.93 (d, 1H); 7.2 (d, 1H);
7.83 (broad s, 1H); 7.94 (s, 2H).
EXAMPLE XXII
4-(3-Cyclohexylmethyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzyl
bromide
[0337] 147
[0338] Preparation is carried out in analogy to the procedure of
Example VII from 2.0 g (4.18 mmol) of benzyl alcohol derivative
from Example XXI and 2.82 g (6.69 mmol) of
dibromotriphenylphosphorane in 40 ml of acetonitrile. After
stirring for 3 hours at room temperature, 0.3 equivalent of
dibromotriphenylphosphorane is again added. The mixture is
additionally stirred for 5 hours at 70.degree. C. and afterwards
overnight at room temperature. The purification of the product is
carried out on silica gel using toluene as eluent.
[0339] Yield: 0.96 g (40.2%)
[0340] MS (ESI): 534 ([M+H].sup.+, 100%)
[0341] R.sub.f: 0.76 (toluene:ethyl acetate=9:1)
[0342] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=0.92 (m, 2H);
1.16 (m, 4H); 1.5 (m, 1H); 1.66 (m, 4H); 2.5 (d, 2H); 4.58 (s, 2H);
6.69 (dd, 1H); 6.83 (d, 1H); 6.95 (d, 1H); 7.21 (d, 1H); 7.35
(broad s, 1H); 7.95 (s, 2H).
EXAMPLE XXIII
4-(3-cyclohexylmethyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-phenylacet-
onitrile
[0343] 148
[0344] Preparation is carried out in analogy to the procedure of
Example VIII from 0.85 g (1.59 mmol) of benzyl bromide from Example
XXII with 0.1 g (1.99 mmol) of sodium cyanide in 5 ml of
dimethylformamide and 0.5 ml of water at 50.degree. C. in 1.5
hours. The chromatography of the crude product is carried out on
silica gel 60 by means of toluene.
[0345] Yield: 0.32 g (37.7%)
[0346] MS (ESI): 481 ([M+H].sup.+, 100%)
[0347] HPLC: R.sub.t=5.67 (90,0%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0348] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=0.92 (m, 2H);
1.16 (m, 4H); 1.5 (m, 1H); 1.67 (m, 4H); 2.5 (d, 2H); 3.92 (s, 2H);
6.69 (dd, 1H); 6.8 (d, 1H); 6.95 (d, 1H); 7.22 (d, 1H); 7.84 (broad
s, 1H); 7.91 (s, 2H).
PREPARATION EXAMPLES
EXAMPLE 1
Methyl
3-({4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}amino)-3--
oxo-propanoate
[0349] 149
[0350] 0.2 g (0.68 mmol) of
4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethy- laniline (Example
XV) are introduced into 2 ml of acetone with 76 mg (0.75 mmol) of
triethylamine and the mixture is treated at 0.degree. C. with 102
mg (0.75 mmol) of methyl malonyl chloride. It is stirred for 1 h,
diluted with dichloromethane and extracted with sodium chloride
solution and with NaHCO.sub.3 solution. The organic phase is dried
and the solvent is removed in vacuo. 211 mg (74%) of methyl
3-({4-[(3-isopropyl-1H-indol--
5-yl)oxy]-3,5-dimethylphenyl}amino)-3-oxo-propanoate are
obtained.
[0351] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29, d, 6H;
2.16, s, 6H; 3.05, hept., 1H; 3.50, s, 2H; 3.81, s, 3H; 6.72, dd,
1H; 6.88, d, 1H; 6.95, d, 1H; 7.25, m, 1H; 7.30, s, 2H; 7.77, s,
broad, 1H.
EXAMPLE 2
3-(
{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}amino)-3-oxopro-
panoic acid
[0352] 150
[0353] 50 mg of methyl
3-({4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethyl-
-phenyl}-amino)-3-oxo-propanoate (Example 1) are stirred in 2 ml of
ethanol with 30 mg of sodium hydroxide for 30 minutes. The solvent
is removed in vacuo. The mixture is taken up in ether/water, the
organic phase is dried and the solvent is removed in vacuo. 23 mg
(46%) of
3-({4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphen-yl}amino)-3-oxopr-
opanoic acid are obtained.
[0354] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): .delta.=1.18, d, 6H;
2.02, s, 6H; 2.92, hept., 1H; 6.52, dd, 1H; 6.64, d, 1H; 7.02, s,
2H; 7.18, d, 1H; 7.32, s, 2H.
EXAMPLE 3
Ethyl
N-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}glycinate
[0355] 151
[0356] 210 mg of
4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylaniline (Example XV)
are brought under reflux with 119 mg of ethyl bromoacetate and 117
mg of sodium acetate in 10 ml of ethanol for 24 h. After addition
of water, the mixture is extracted with ether, and the organic
phase is dried and concentrated in a rotary evaporator. By
chromatographic purification (cyclohexane/ethyl acetate), 143 mg
(53%) of ethyl
N-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}glycinate
are obtained.
[0357] .sup.1H-NMR (300 MHz, CDCl.sub.3):.delta.=1.27, d, 6H; 1.31,
t, 3H; 2.09, s, 6H; 3.06, hept., 1H; 3.92, s, 2H; 4.12, s, broad,
1H; 4.26, quart., 2H; 6.38, s, 2H; 6.72, dd, 1H; 6.91, dd, 2H;
7.20, d, 1H; 7.77, s, broad, 1H.
EXAMPLE 4a
Methyl 3-(
{3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}ami-
no)-3-oxo-propanoate
[0358] 152
[0359] 131 mg of
3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylanili- ne
(Example III) are dissolved in 3 ml of acetone with 46 mg of
triethylamine and treated dropwise with 62 mg of methyl malonyl
chloride at 0.degree. C. The reaction mixture is stirred for 3
hours at room temperature, poured onto 20 ml of dichloromethane,
and the organic phase is washed with sodium chloride solution,
dried over sodium sulphate and concentrated in a rotary evaporator.
By chromatographic purification (cyclohexane/ethyl acetate), 134 mg
of methyl 3-({3-chloro-4-[(3-isopropy-
l-1Hindol-5-yl)oxy]-5-methylphenyl}amino)-3-oxo-propanoate are
obtained.
[0360] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
2.20, s, 3H; 3.07, sept., 1H; 3.50, s, 2H; 3.83, s, 3H; 6.77, dd,
1H; 6.92, d, 1H; 6.95, d, 1H; 7.24, m, 1H; 7.36, d, 1H; 7.65, d,
1H; 7.81, s, broad, 1H; 9.24, s, broad, 1H.
EXAMPLE 4b
Ethyl
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl
}amino)-3oxo-propanoate
[0361] 153
[0362] In analogy to Example 4a, starting from 2.50 g (7.94 mmol)
of 3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylaniline
(Example III) and 1.26 g (7.94 mmol) of ethyl malonyl chloride,
3.65 g (99% of theory) of ethyl
3-({3-chloro-4-[(3-iso-propyl-1H-indol-5-yl)oxy]-5-methylphenyl}-
amino)-3-oxo-propanoate are obtained.
[0363] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
1.34, t, 3H; 2.19, s, 3H; 3.08, sept., 1H; 3.49, s, 2H; 4.27,
quart., 2H; 6.76, dd, 1H; 6.93, m, 2H; 7.22, m, 1H; 7.36, d, 1H;
7.66, d, 1H; 7.80, broad s, 1H; 9.32, broad s, 1H.
EXAMPLE 4c
Isopropyl
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}--
amino)-3-oxo-propanoate
[0364] 154
[0365] This compound can be prepared starting from
3-chloro-4-[(3-isopropy- l-1H-indol-5-yl)oxy]-5-methylaniline
(Example III) in analogy to Example 4a.
EXAMPLE 4d
2-Hydroxyethyl
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphe-
nyl}-amino)-3-oxopropanoate
[0366] 155
[0367] This compound can be prepared starting from
3-chloro-4-[(3-isopropy- l-1H-indol-5-yl)oxy]-5-methylaniline
(Example III) or methyl 3-(
{3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-3-oxo--
propanoate (Example 4a) according to methods known from the
literature.
EXAMPLE 5
N-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}glycine
[0368] 156
[0369] 56 mg of ethyl
N-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylph-
enyl}glycinate (Example 3) are stirred in 7 ml of dioxane with 1.5
ml of 1N sodium hydroxide for 2 hours at room temperature. The
mixture is poured onto water, rendered acidic using 1N hydrochloric
acid, extracted with ethyl acetate, the extract is dried and the
solvent is removed in vacuo. 51 mg of
N-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-dimethyl-phenyl- }glycine
are obtained
[0370] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29, d, 6H;
2.10, s, 6H; 3.07, sept., 1H; 3.70, s, 2H; 6.41, s, 2H; 6.73, m,
1H; 6.91, m, 2H; 7.21, d, 1H; 7.77, s, broad, 1H.
EXAMPLE 6
3-(
{3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-3-o-
xo-propionic acid
[0371] 157
[0372] 101 mg of methyl
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5--
methyl-phenyl}amino)-3-oxo-propanoate (Example 4a) are dissolved in
2 ml of ethanol and 1 ml of 1N sodium hydroxide solution, the
solution is stirred at room temperature for 1 hour and the solvent
is removed in vacuo. The residue is rendered acidic, extracted with
ethyl acetate, the extract is dried over sodium sulphate and the
solvent is removed in vacuo. 87 mg of
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylp-
henyl}amino)-3-oxopropionic acid are obtained.
[0373] .sup.1H-NMR (300 MHz, MeOH-d.sub.4): .delta.=1.25, d, 6H;
2.16, s, 3H; 2.99, sept., 1H; 3.45, s, 2H; 6.69, dd, 1H; 6.76, d,
1H; 6.96, s, 1H; 7.23, d, 1H; 7.38, d, 1H; 7.73, d, 1H.
EXAMPLE 6a
Potassium
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}a-
mino)-3-oxopropanoate
[0374] 158
[0375] 1.16 g (2.89 mmol) of
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)ox-
y]-5-methyl-phenyl}amino)-3-oxopropionic acid (Example 6) are
dissolved in 15 ml of THF and treated dropwise at 0.degree. C. with
5.67 ml of a 0.51 molar potassium hydroxide solution. The reaction
mixture is stirred for one hour and the solvent is then removed in
vacuo. By co-evaporation with toluene, 1.25 g (99% of theory) of
potassium 3-({3-chloro-4-[(3-isopropyl-
-1H-indol-5-yl)oxy]-5-methylphenyl}-amino)-3-oxopropanoate are
obtained
[0376] .sup.1H-NMR (200 MHz, DMSO-d.sub.6): .delta.=1.20, d, 6H;
2.10, s, 3H; 2.83, s, 2H; 2.96, sept., 1H; 6.62, dd, 1H; 6.73, d,
1H; 7.04, d, 1H; 7.26, m, 3H; 7.84, d, 1H; 10.70, s, broad, 1H;
13.03, s, broad, 1H.
EXAMPLE 6b
Sodium
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amin-
o)-3-oxopropanoate
[0377] 159
[0378] This compound is obtained in a manner analogous to Example
6a starting from
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphe-
nyl}amino)-3-oxo-propionic acid (Example 6) and sodium
hydroxide.
EXAMPLE 6c
Magnesium
bis[3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphen-
yl}-amino)-3-oxopropanoate]
[0379] 160
[0380] This compound is obtained in a manner analogous to Example
6a starting from
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphe-
nyl}amino)-3-oxo-propionic acid (Example 6) and magnesium
methoxide.
EXAMPLE 6d
Calcium
bis[3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl-
}-amino)-3-oxopropanoate]
[0381] 161
[0382] This compound is obtained in a manner analogous to Example
6a starting from
3-({3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphe-
nyl}amino)-3-oxo-propionic acid (Example 6) and calcium
hydroxide.
EXAMPLE 7
Methyl
3-({3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-3--
oxo-propanoate
[0383] 162
[0384] 139 mg of
3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]aniline (Example IV)
are dissolved with 46 mg of triethylamine in 3 ml of acetone and
treated dropwise at 0.degree. C. with 62 mg of methyl malonyl
chloride. The reaction mixture is stirred at room temperature for
one hour, poured onto 20 ml of dichloromethane, and the organic
phase is washed with sodium chloride solution, dried over sodium
sulphate and concentrated in a rotary evaporator. By
chromatographic purification (cyclohexane/ethyl acetate), 162 mg of
methyl 3-({3,5-dichloro-4-[(3-isop-
ropyl-1H-indol-5-yl)-oxy]phenyl}amino)-3-oxopropanoate are
obtained
[0385] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29, d, 6H;
3.09, sept., 1H; 3.47, s, 2H; 3.82, s, 3H; 6.80, dd, 1H; 6.96, m,
1H; 7.19, s, 1H; 7.24, m, 1H; 7.70, s, 2H; 7.82, s, broad, 1H;
9.43, s, broad, 1H.
EXAMPLE 8
3-({3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-3-oxoprop-
ionic acid
[0386] 163
[0387] 193 mg of methyl
3-((3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy-
]phenyl}-amino)-3-oxopropanoate (Example 7) are stirred in 3 ml of
ethanol with 1 ml of 1N NaOH for one hour at room temperature. The
solvent is removed in vacuo and the residue is taken up in
dichloromethane. The mixture is shaken with water, the organic
phase is dried and the solvent is removed in vacuo. By stirring
with diethyl ether, 143 mg of
3-({3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-3-oxopro-
pionic acid are obtained.
[0388] .sup.1H-NMR (300 MHz, MeOH-d.sub.4): .delta.=1.27, d, 6H;
3.00, sept., 1H; 3.35, s, 2H; 6.70, dd, 1H; 6.79, m, 1H; 6.97, s,
1H; 7.23, d, 1H; 7.79, s, 2H.
EXAMPLE 9
Ethyl
N-{3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}glycin-
ate
[0389] 164
[0390] 120 mg of
3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylanili- ne
(Example III) are heated to reflux with 62 mg of sodium acetate and
63 mg of ethyl bromoacetate in 5 ml of ethanol for 17 hours. A
further 21 mg of ethyl bromoacetate are added and the mixture is
refluxed for 3 hours. The solvent is removed in vacuo, the residue
is taken up with water and dichloromethane, the organic phase is
washed with saturated sodium chloride solution, dried and the
solvent is removed in vacuo. Chromatographic purification
(cyclohexane/ethyl acetate) affords 56 mg of ethyl
N-{3-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}glyci-
nate.
[0391] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.29, d, 6H;
1.32, t, 3H; 2.13, s, 3H; 3.08, sept., 1H; 3.91, s, 2H; 4.28,
quart, 2H; 6.43, d, 1H; 6.56, d, 1H; 6.77, dd, 1H; 6.94, d, 1H;
7.22, d, 1H; 7.78, s, broad, 1H.
EXAMPLE 10
Ethyl
N-{3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}glycinate
[0392] 165
[0393] 100 mg of
3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]aniline (Example IV)
are heated to reflux with 49 mg of sodium acetate and 50 mg of
ethyl bromoacetate in 5 ml of ethanol for 17 hours. A further 21 mg
of ethyl bromoacetate are added and the mixture is refluxed for 2
hours. The solvent is removed in vacuo, the residue is taken up
with water and dichloromethane, the organic phase is washed with
saturated sodium chloride solution, dried and the solvent is
removed in vacuo. Chromatographic purification (cyclohexane/ethyl
acetate) affords 22 mg of ethyl
N-{3,5-dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}glycinate.
[0394] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): .delta.=1.21, t, 3H;
1.22, d, 6H; 2.96, m 1H; 4.00, m, 2H; 4.15, quart., 2H; 6.63, m,
1H; 6.76, d, 1H; 6.77, s, 2H; 7.06, d, 1H; 7.24,
EXAMPLE 11
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethylphenylacetic
acid
[0395] 166
[0396] A mixture of 5 ml of concentrated sulphuric acid and 5 ml of
water is added dropwise to a solution of 0.35 g (0.82 mmol) of
nitrile derivative from Example VIII in 5 ml of acetic acid (100%
strength). The reaction solution is stirred at 105.degree. C. for 4
hours, then cooled to room temperature and treated with ice-cold
water and ethyl acetate. The organic phase is separated off, the
aqueous solution is extracted again with ethyl acetate, and the
combined organic phases are dried over sodium sulphate, filtered
and concentrated to give an oil. The crude product (120.3 mg) is
chromatographed on silica gel 60 by means of methylene
chloride/methanol (95:5 and 95:11).
[0397] Yield: 55 mg (15.3%)
[0398] MS (DCI): 446 ([M+H].sup.+, 100%)
[0399] R.sub.f: 0.38 (methylene chloride:methanol 9:1)
[0400] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
3.05, quin, 1H; 3.81, s, 2H; 6.69, dd, 1H; 6.89, d, 1H; 6.94, d,
1H; 7.21, d, 1H; 7.8, broad s, 1H; 7.88, s, 2H.
EXAMPLE 12
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-benzyltetrazole
[0401] 167
[0402] 251 mg (4.69 mmol) of ammonium chloride and 305 mg (4.69
mmol) of sodium azide are added to a solution of 200 mg (0.469
mmol) of nitrile derivative from Example VIII in 8 ml of
dimethylformamide and the solution is boiled under reflux for 4
hours. The solution is then highly concentrated, treated with 6N
hydrochloric acid and extracted three times with ethyl acetate. The
combined organic phases are dried, filtered and concentrated to an
oil in vacuo. The crude product is dissolved in dichloromethane and
chromatographed on silica gel 60 using dichloromethane with
addition of methanol in the gradient mode (90:5 to 90:40).
[0403] Yield: 126 mg (57.3%)
[0404] MS (ESI): 470 ([M+H].sup.+, 100%)
[0405] R.sub.f: 0.30 (dichloromethane:methanol=9:1)
[0406] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.27, d, 6H;
3.06, quin, 1H; 4.49, s, 2H; 6.67, dd, 1H; 6.88, d, 1H; 6.94, d,
1H; 7.2, d, 1H; 7.84, broad s, 1H; 7.92, s, 2H; 8.01, s, 1H.
EXAMPLE 13
Ethyl 4-(3-isopropyl-1H-indol-5-yloxy)-3,5-bis-tri
fluoromethyl-cinnamate
[0407] 168
[0408] 1.0 g (2.41 mmol) of aldehyde derivative from Example V is
dissolved in 10 ml of toluene and 0.92 g (2.65 mmol) of
ethoxycarbonylmethylene-triphenylphosphorane is introduced in
portions. After stirring at room temperature for 2 days, the
reaction mixture is concentrated to a half of the volume and
chromatographed on silica gel 60 by means of toluene.
[0409] Yield: 1.076 g (88.4%)
[0410] MS (ESI): 486 ([M+H].sup.+, 100%)
[0411] R.sub.f: 0.68 (toluene:ethyl acetate=8:2)
[0412] HPLC: R.sub.t=5.44 (94.5%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/minute; 210
nm
[0413] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.27, d, 6H;
1.37, t, 3H; 3.05, quin, 1H; 4.3, quart, 2H; 6.55, broad d, 1H;
6.72, dd, 1H; 6.87, d, 1H; 6.95, d, 1H; 7.21, d, 1H; 7.73, broad d,
1H; 7.84, broad s, 1H; 8.04, s, 2H.
EXAMPLE 14
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethyl-cinnamic
acid
[0414] 169
[0415] 0.23 g (0.46 mmol) of ethyl cinnamate derivative from
Example 13 are dissolved in 10 ml of dioxane, 4 ml of 1 molar
sodium hydroxide solution are added and the mixture is stirred for
5 hours at room temperature. The reaction solution is acidified to
pH 4 using 1N hydrochloric acid, treated with ethyl acetate and the
aqueous phase is extracted a further two times with ethyl acetate.
The combined organic phases are washed with sodium chloride
solution, dried over sodium sulphate, filtered, concentrated and
dried overnight in a high vacuum.
[0416] Yield: 0.175 g (79.0%)
[0417] MS (DCI): 475 ([M+NH.sub.4].sup.+, 100%)
[0418] HPLC: R.sub.t=4.99 (96.3%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml minute; 210
nm
[0419] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
3.06, quin, 1H; 6.59, broad d, 1H; 6.73, dd, 1H; 6.88, d, 1H; 6.97,
d, 1H; 7.23, d, 1H; 7.83, broad s and broad d, 2H; 8.09, s, 2H.
EXAMPLE 15
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethylphenylpropionic
acid
[0420] 170
[0421] 150 mg (0.328 mmol) of cinnamic acid derivative from Example
14 are dissolved in 10 ml of methanol, treated with 75 mg of
palladium on active carbon (10% strength) and hydrogenated for 18
hours at hydrostatic hydrogen pressure. The palladium catalyst is
filtered off with suction through kieselguhr, washed with methanol
and the filtrate is concentrated to give a solid product.
[0422] Yield: 86.2 mg (57.2%)
[0423] MS (LC): 460 ([M+H].sup.+, 100%)
[0424] R.sub.f: 0.76 (methylene chloride:methanol=10:1)
[0425] .sup.1H-NMR (200 MHz, DMSO-d.sub.6): .delta.=1.19, d, 6H;
2.7, t, 2H; 2.95, quin, 1H; 3.03, t, 2H; 6.58, dd, 1H; 6.7, d, 1H;
7.08, d, 1H; 7.24, d, 1H; 8.05, s, 2H; 10.72, d, 1H; 12.25, broad
s, 1H.
EXAMPLE 16
{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
[0426] 171
[0427] 0.24 g (0.46 mmol) of
tert-butyl-[4-({l-[tert-butyl-(dimethyl)silyl-
]-3-isopropyl-1H-indol-5-yl}oxy)-3,5-dimethylphenoxy]acetate
(Example XIII) is introduced dissolved in 5 ml of ethanol and 2.5
ml (2.50 mmol) of 1N sodium hydroxide solution are added. The batch
is stirred at room temperature for 2.5 h. The solvent is evaporated
in a rotary evaporator, the batch is diluted with 50 ml of water
and the mixture is acidified with 1N hydrochloric acid solution.
The aqueous phase is extracted twice with ethyl acetate, the
combined organic phases are dried and the solvent is removed in
vacuo. 0.186 g (87.3%) of {4-[(3-isopropyl-1H-indol-5-yl)ox-
y]-3,5-dimethyl-phenoxy}acetic acid is obtained
[0428] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.28, d, 6H;
2.10, s, 6H; 2.96, m, 1H; 3.08, sept., 1H; 4.58, s, 2H; 6.68, s,
3H; 6.90, dd, 2H; 7.81, s, 1H.
EXAMPLE 17
4-(3-Isopropyl-1H-indol-5-yloxy)-3,5-dichlorophenylacetic acid
[0429] 172
[0430] Firstly, 5 ml of conc. sulphuric acid and then 5 ml of water
are added dropwise to a solution of 0.43 g (0.90 mmol) of nitrile
derivative from Example XIX in 10 ml of dioxane. The reaction
mixture is stirred for 4 hours at 100.degree. C., then poured onto
ice and extracted twice with ethyl acetate. The combined organic
phases are washed with sodium chloride solution, dried over sodium
sulphate, filtered and concentrated in vacuo. The crude product is
chromatographed on silica gel 60 by means of toluene/ethyl acetate
(1:1) in the isocratic mode.
[0431] Yield: 0.266 g (68.7%)
[0432] MS (DCI): 395 ([M+NH.sub.4].sup.+, 100%)
[0433] HPLC: R.sub.t=4.79 (87.8%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0434] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.4 (d, 6H); 3.1
(quin, 1H); 3.65 (s, 2H); 6.76 (dd, 1H); 6.95 (d, 1H); 7.03 (d,
1H); 7.24 (d, 1H); 7.34 (s, 2H); 7.81 (broad s, 1H).
EXAMPLE 18
5-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethylphenyl}-imida-
zolidin-2,4-dione
[0435] 173
[0436] 3.0 g (7.22 mmol) of aldehyde from Example V dissolved in 30
ml of ethanol are added to a solution of 0.581 g (14.4 mmol) of
sodium cyanide and 3.63 g (36.1 mmol) of ammonium carbonate in 30
ml of water and the mixture is stirred for 24 hours at 60.degree.
C. Ethanol is then distilled off from the reaction solution, it is
diluted with water, acidified to pH 2 with 1N hydrochloric acid
with ice-cooling and extracted twice with ethyl acetate. After
drying and distilling off the solvent, the crude product (4.03 g)
is chromatographed on silica gel 60 using methylene chloride with
addition of a little methanol in the ratio 20:1 to 20:2.5.
[0437] Yield: 2.73 g (78.1 %)
[0438] MS (ESI): 486 ([M+H].sup.+, 100%)
[0439] HPLC: R.sub.t=4.58 (85.1%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0440] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.26 (d, 6H);
3.06 (quin., 1H); 5.29 (s, 1H); 6.23 (s, 1H); 6.65 (dd, 1H); 6.9
(d, 1H); 6.95 (d, 1H); 7.2 (d, 1H); 7.8 (broad s, 1H); 7.97 (s,
2H); 8.27 (broad s, 1H).
EXAMPLE 19
DL-Amino-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethylphenyl
}-acetic acid
[0441] 174
[0442] 1.0 g (2.06 mmol) of hydantoin from Example 18 are heated to
100.degree. C. with 0.493 g (20.6 mmol) of lithium hydroxide in 15
ml of water overnight. The reaction solution is cooled to 0.degree.
C. and directly reacted further with di-tert-butyl dicarbonate
(Example 20).
[0443] R.sub.f: 0.39 (methylene cloride:methanol=8:2)
EXAMPLE 20
DL-tert-Butoxycarbonylamino-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-tr-
ifluoro-methylphenyl}-acetic acid
[0444] 175
[0445] The reaction solution from Example 19 (about 2.06 mmol=100%)
is treated with 50 ml of dioxane and reacted dropwise at O.degree.
C. with 0.899 g (4.12 mmol) of di-tert-butyl dicarbonate dissolved
in 5 ml of dioxane. The reaction mixture is then allowed to come to
room temperature and stirred for 2 hours at room temperature. After
distilling off dioxane, the reaction solution is acidified to pH 2
at 0.degree. C. using 1N hydrochloric acid and extracted twice with
ethyl acetate. The combined ethyl acetate phases are washed with
sodium chloride solution, dried, filtered and concentrated. The
crude product (1.234 g) is chromatographed on silica gel 60 using
methylene chloride/methanol (9:1) in the isocratic mode.
[0446] Yield: 0.271 g (23.5%)
[0447] A 2nd fraction of 0.531 g (HPLC concentration: 64.0%) is
obtained.
[0448] MS (LC-MS): 561 ([M+H].sup.+, 100%)
[0449] HPLC: R.sub.t=0.503 (91.4%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
[0450] .sup.1H-NMR (200 MHz, d.sub.6-DMSO): .delta.=1.18 (d, 6H);
1.38 (s, 9H); 2.93 (m, 1H); 3.33 (broad s, 1H); 4.99 (d, 1H); 6.59
(d, 1H); 6.7 (s, 1H); 7.08 (d, 1H); 7.25 (d, 1H); 8.1 (s, 2H);
10.75 (s, 1H).
EXAMPLE 21
DL-Amino-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-tri
fluoromethylphenyl}-acetic acid acetate salt
[0451] 176
[0452] 0.526 g (0.945 mmol) of tert-butoxycarbonyl-protected amino
acid from Example 20 is dissolved in 7 ml of dichloromethane,
cooled to 0.degree. C. and treated dropwise under argon with 7 ml
of trifluoroacetic acid. The solution is then stirred for 45 min at
room temperature, subsequently concentrated to give an oil, the
oily residue is stirred with ether and ether is distilled off.
[0453] Yield: 0.526 g (as trifluoroacetate salt)
[0454] The residue is dissolved in 20% strength acetic acid (20 ml)
with addition of 10 ml of methanol and sent through a column packed
with 80 ml of Amberlite IR-67 (acetate form; Fluka). The column is
subsequently washed with water/methanol mixture (1:1), and the
eluate is freed from methanol in vacuo and lyophilized.
[0455] Yield: 120 mg (27.8%)
[0456] MS (EI): 460 ([M].sup.+, 14%)
[0457] HPLC: R.sub.t=4,29 (79.8%) 0.5% HClO.sub.4/acetonitrile
Kromasil column C18 (60.times.2 mm) flow: 0.75 ml/min; 210 nm
EXAMPLE 22
5-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethyl-benzylidene}-
-thia-zolidine-2,4-dione
[0458] 177
[0459] A mixture of 0.52 g (1.25 mmol) of aldehyde derivative from
Example V, 0.21 g (1.63 mmol) of 2,4-thiazolidine-2,4-dione, 0.2 g
(1.63 mmol) of benzoic acid and 0.14 g (1.63 mmol) of piperidine in
47.5 ml of toluene are boiled under reflux overnight in the
presence of molecular sieve 4 .ANG. powder. The reaction solution
is then cooled to room temperature, diluted with 47.5 ml of
toluene, and the molecular sieve is filtered off with suction and
washed with ethyl acetate. The organic filtrate is washed twice
with ammonium chloride solution, dried, filtered and concentrated
in vacuo. The thioazolidine dione derivative is obtained by
chromatography on silica gel 60 by means of toluene/ethyl acetate
(10:1) in the isocratic mode.
[0460] Yield: 50 mg (4.9%)
[0461] MS (ESI): 515 ([M+H].sup.+, 100%)
[0462] HPLC: R.sub.t=3.72 (63.2%) 0.3 g of 30% strength HCl per 1 l
of H.sub.2O Symmetry column C18 (150.times.2.1 mm) flow: 0.9
ml/min; 210 nm
EXAMPLE 23
6-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethylphenyl}-[1,3]-
-thiazinan-2,4-dione
[0463] 178
[0464] The thiazine derivative is formed as a further product in
the preparation of the benzylidene-2,4-thiazolidine dione
derivative (Example 22).
[0465] Yield: 0.123 g (14.7%)
[0466] MS (LC): 517 ([M+H].sup.+, 100%)
[0467] HPLC: R.sub.t=3.26 (77.3%) 0.3 g of 30% strength HCl per 1 l
of H.sub.2O Symmetry column C18 (150.times.2.1 mm) flow: 0.9 m/min;
210 nm
EXAMPLE 24
3-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethyl-benzylidene}-
-dihydro-furan-2-one
[0468] 179
[0469] 0.36 g (0.87 mmol) of aldehyde derivative from Example V are
dissolved in 10 ml of toluene and 0.36 g (1.04 mmol) of
butyrolactonylidene-triphenylphosphorane are introduced in
portions. After stirring at room temperature for 3 days, the
reaction mixture is filtered, and the filtrate is concentrated to
half of the volume and chromatographed on silica gel 60 by means of
toluene/ethyl acetate (9:1).
[0470] Yield: 0.334 g (72.5%)
[0471] MS (DCI): 501 ([M+NH.sub.4].sup.+, 100%)
[0472] R.sub.f: 0.87 (toluene:ethyl acetate=9:1)
[0473] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.27 (d, 6H);
3.05 (quin, 1H); 3.31 (sext, 2H); 4.55 (t, 2H); 6.71 (dd, 1H); 6.88
(d, 1H); 6.96 (d, 1H); 7.2 (d, 1H); 7.62 (t, 1H); 7.84 (broad s,
1H); 8.03 (s, 2H).
EXAMPLE 25
3-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethyl-benzyl}-dihy-
dro-furan-2-one
[0474] 180
[0475] 0.2 g (0.38 mmol) of benzylidene compound from Example 24
are dissolved in 100 ml of methanol and hydrogenated with hydrogen
for 18 hours in the presence of palladium on active carbon. The
catalyst is filtered off through kieselguhr and the filtrate is
concentrated in vacuo. The crude product is purified by
chromatography on silica gel 60 in the isocratic gradient mode
using toluene/ethyl acetate (10:1).
[0476] Yield: 94 mg (48.7%)
[0477] MS (ESI): 486 ([M+H].sup.+, 100%)
[0478] R.sub.f: 0.35 (toluene:ethyl acetate=9:1)
[0479] .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta.=1.28 (d, 6H);
2.04 (m, 1H); 2.37 (m, 1H); 2.91 (m, 2H); 3.05 (quin, 1H); 3.4
(quart, 1H); 4.23 (m, 1H); 4.39 (sext, 1H); 6.69 (dd, 1H); 6.85 (d,
1H); 6.94 (d, 1H); 7.2 (d, 1H); 7.77 (s, 2H); 7.8 (s, 1H).
EXAMPLE 26
Ethyl
5-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethylphenyl}-
-3-oxo-pent-4-ene-carboxylate
[0480] 181
[0481] Analogously to the procedure of Example 24, 0.35 g (0.84
mmol) of aldehyde derivative from Example V is reacted with 0.36 g
(0.93 mmol) of ethyl 4-(tri-phenylphosphoranylidene)-acetoacetate
in 10 ml of toluene for 2 days at room temperature and then for 18
hours at 75.degree. C. and 6 hours at 120.degree. C. The crude
product is purified by column chromatography on silica gel 60 using
toluene.
[0482] Yield: 0.24 g (47.3%)
[0483] MS (ESI): 528 ([M+H].sup.+, 100%)
[0484] HPLC: R.sub.t=6.00 (27.3%) and R.sub.t=5.35 (51.2%); E/Z
mixture 0.5% HClO.sub.4/acetonitrile Kromasil column C18
(60.times.2 mm) flow: 0.75 m/min; 210 nm
EXAMPLE 27
Ethyl
5-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethylphenyl}-
-3-oxo-pentane-carboxylate
[0485] 182
[0486] Analogously to the procedure of Example 25, 0.2 g (0.38
mmol) of 3-oxopentene-4-carboxylic acid derivative from Example 26
is hydrogenated overnight in methanol with palladium on active
carbon under a hydrogen atmosphere. The crude product is
chromatographed on silica gel using toluene/ethyl acetate (10:1) in
the isocratic mode.
[0487] Yield: 89 mg (38.6%)
[0488] MS (ESI): 530 ([M+H].sup.+, 100%)
[0489] R.sub.f: 0.37 (toluene: ethyl acetate=9:1)
[0490] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.28 (d and t,
9H); 3.03 (m, 5H); 3.49 (s, 2H); 4.2 (quart, 2H); 6.7 (dd, 1H);
6.87 (d, 1H); 6.95 (d, 1H); 7.21 (d, 1H); 7.73 (s, 2H); 7.8 (s,
1H).
EXAMPLE 28
Ethyl
5-{4-[(3-isopropyl-1H-indol-5-yl)oxy]-3,5-bis-trifluoromethyl-phenyl-
}-pentane-carboxylate
[0491] 183
[0492] The pentanecarboxylic acid derivative is formed as a
by-product in the catalytic hydrogenation of the
3-oxo-pentenecarboxylic acid derivative in
EXAMPLE 27.
[0493] Yield: 15 mg (6.2%)
[0494] MS (ESI): 516 ([M+H].sup.+, 100%)
[0495] R.sub.f: 0.4 (toluene : ethyl acetate=9:1)
[0496] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=1.28 (d and t,
9H); 1.73 (quin, 3H); 2.39 (m, 2H); 2.78 (m, 2H); 3.04 (sext, 2H);
4.15 (quart, 2H); 6.7 (dd, 1H); 6.86 (d, 1H); 6.93 (d, 1H); 7.21
(d, 1H); 7.71 (s, 2H); 7.8 (broad s, 1H).
EXAMPLE 29
4-(3-Cyclohexylmethyl-1H-indol-5-yloxy)-3,5-bis-trifluoromethylphenylaceti-
c acid
[0497] 184
[0498] The preparation is carried out in analogy to the procedure
of Example 17 from 0.3 g (0.62 mmol) of phenylacetonitrile
derivative from Example XXIII by dissolving the nitrile in 10 ml of
dioxane and treating it with 4 ml of conc. sulphuric acid and 4 ml
of water for 4 hours at 100.degree. C. The crude product is
chromatographed on silica gel 60 by means of toluene/ethyl acetate
(1:1) in the isocratic mode.
[0499] Yield: 65 mg (17.5%)
[0500] MS (ESI): 500 ([M+H].sup.+, 100%)
[0501] HPLC: R.sub.t=5.23 (82.6%)
[0502] 0.5% HClO.sub.4/acetonitrile
[0503] Kromasil column C18 (60.times.2 mm)
[0504] flow: 0.75 ml/min; 210 nm
[0505] R.sub.f: 0.29 (toluene: ethyl acetate=1:1)
[0506] .sup.1H-NMR (200 MHz, CDCl.sub.3): .delta.=0.92 (m, 2H);
1.17 (m, 4H); 1.5 (m, 1H); 1.65 (m 4H); 2.49 (d, 2H); 3.82 (s, 2H);
6.68 (dd, 1H); 6.84 (d, 1H); 6.93 (d, 1H); 7.2 (d, 1H); 7.85 (d and
s, 3H).
[0507] The following can be prepared in an analogous manner:
EXAMPLE 30
{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 31
{4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 32
{4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 33
{4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 34
{4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 35
{3,5-Dimethyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 36
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic acid
EXAMPLE 37
{3,5-Dimethyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 38
{4-[(3-Hexyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic acid
EXAMPLE 39
{4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 40
{4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-dimethylphenoxy}acetic
acid
EXAMPLE 41
(4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenoxy)acetic
acid
EXAMPLE 42
(4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenoxy)acetic
acid
EXAMPLE 43
(4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenoxy)acetic
acid
EXAMPLE 44
(4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenoxy)acetic
acid
EXAMPLE 45
{3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 46
{3,5-Dichloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 47
{3,5-Dichloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 48
{3,5-Dichloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 49
(3,5-Dichloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 50
(3,5-Dichloro-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxyl acetic
acid
EXAMPLE 51
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-dichlorophenoxy}acetic acid
EXAMPLE 52
{3,5-Dichloro-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 53
{3,5-Dichloro-4-[(3-hexyl-1H-indol-5-yl)oxy]phenoxy}acetic acid
EXAMPLE 54
{3,5-Dichloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 55
{4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-dichlorophenoxy}acetic
acid
EXAMPLE 56
(3,5-Dichloro-4-{
[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic acid
EXAMPLE 57
(3,5-Dichloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 58
(3,5-Dichloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy)
phenoxy)acetic acid
EXAMPLE 59
(3,5-Dichloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 60
{3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 61
{3,5-Dibromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 62
{3,5-Dibromo-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 63
{3,5-Dibromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 64
{3,5-Dibromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 65
{3,5-Dibromo-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic acid
EXAMPLE 66
{3,5-Dibromo-4-[(3-butyl-1H-indol-5-yl)oxy]phenoxy}acetic acid
EXAMPLE 67
{3,5-Dibromo-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic acid
EXAMPLE 68
{3,5-Dibromo-4-[(3-hexyl-1H-indol-5-yl)oxy]phenoxy}acetic acid
EXAMPLE 69
{3,5-Dibromo-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 70
{3,5-Dibromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 71
(3,5-Dibromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 72
(3,5-Dibromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 73
(3,5-Dibromo-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 74
(3,5-Dibromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 75
[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 76
[4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acet-
ic acid
EXAMPLE 77
[4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]aceti-
c acid
EXAMPLE 78
[4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acet-
ic acid
EXAMPLE 79
[4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]aceti-
c acid
EXAMPLE 80
[4-[(3-Propyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 81
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 82
[4-[(3-Pentyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 83
[4-[(3-Hexyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 84
[4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 85
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 86
[4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)pheno-
xy]-acetic acid
EXAMPLE 87
[4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phen-
oxy]-acetic acid
EXAMPLE 88
[4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)pheno-
xy]-acetic acid
EXAMPLE 89
[4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phen-
oxy]-acetic acid
EXAMPLE 90
[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 91
[4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(tri
fluoromethyl)phenoxy]-acetic acid
EXAMPLE 92
[4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3-methyl-S-(trifluoromethyl)phenoxy]a-
cetic acid
EXAMPLE 93
[4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]-
-acetic acid
EXAMPLE 94
[4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]--
acetic acid
EXAMPLE 95
[3-Methyl-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]aceti-
c acid
EXAMPLE 96
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 97
[3-Methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]
-5-(trifluoromethyl)phenoxy]acet- ic acid
EXAMPLE 98
[4-[(3-Hexyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 99
[4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3-methyl-5-(tri
fluoromethyl)phenoxy]ac- etic acid
EXAMPLE 100
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 101
[4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)p-
henoxy]-acetic acid
EXAMPLE 102
[4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)-
phenoxy]-acetic acid
EXAMPLE 103
[4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)p-
henoxy]-acetic acid
EXAMPLE 104
[4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)-
-phenoxy]acetic acid
EXAMPLE 105
{3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 106
{3-Bromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 107
{3-Bromo-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 108
{3-Bromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 109
{3-Bromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 110
{3-Bromo-5-methyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 111
{3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 112
{3-Bromo-5-methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 113
{3-Bromo-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 114
{3-Bromo-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 115
{3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 116
(3-Bromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)aceti-
c acid
EXAMPLE 117
(3-Bromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 118
(3-Bromo-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)aceti-
c acid
EXAMPLE 119
(3-Bromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 120
{3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenoxy)
acetic acid
EXAMPLE 121
{3-Chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 122
{3-Chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 123
{3-Chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 124
{3-Chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 125
{3-Chloro-5-methyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 126
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenoxy}acetic
acid
EXAMPLE 127
{3-Chloro-5-methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 128
{3-Chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 129
{3-Chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 130
{4-[(3-sec-butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenoxy}acetic
acid
EXAMPLE 131
(3-Chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 132
(3-Chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)ace-
tic acid
EXAMPLE 133
(3-Chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 134
(3-Chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)ace-
tic acid
EXAMPLE 135
{3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 136
{3-Bromo-5-chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenoxy)
acetic acid
EXAMPLE 137
{3-Bromo-5-chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 138
{3-Bromo-5-chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid.
EXAMPLE 139
{3-Bromo-5-chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 140
{3-Bromo-5-chloro-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 141
{3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-chlorophenoxy}acetic
acid
EXAMPLE 142
{3-Bromo-5-chloro-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 143
{3-Bromo-5-chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 144
{3-Bromo-5-chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 145
{3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-chlorophenoxy}acetic
acid
EXAMPLE 146
(3-Bromo-5-chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenoxy)aceti-
c acid
EXAMPLE 147
(3-Bromo-5-chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenoxy)acet-
ic acid
EXAMPLE 148
(3-Bromo-5-chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}phenoxy)aceti-
c acid
EXAMPLE 149
(3-Bromo-5-chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}phenoxy)acet-
ic acid
EXAMPLE 150
[3-Chloro-4-([3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 151
3-Chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]a-
cetic acid
EXAMPLE 152
[3-Chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]a-
cetic acid
EXAMPLE 153
[3-Chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]-
acetic acid
EXAMPLE 154
[3-Chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]a-
cetic acid
EXAMPLE 155
[3-Chloro-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]aceti-
c acid
EXAMPLE 125
{3-Chloro-5-methyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 126
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenoxy}acetic
acid
EXAMPLE 127
{3-Chloro-5-methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenoxy}acetic
acid
EXAMPLE 128
{3-Chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 129
{3-Chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-methylphenoxy}acetic
acid
EXAMPLE 130
{4-[(3-sec-butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenoxy}acetic
acid
EXAMPLE 131
(3-Chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 132
(3-Chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]
oxy}-5-methylphenoxy)ac- etic acid
EXAMPLE 133
(3-Chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-methylphenoxy)acet-
ic acid
EXAMPLE 156
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 157
[3-Chloro-4-[(3-pentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]aceti-
c acid
EXAMPLE 158
[3-Chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 159
[3-Chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ace-
tic acid
EXAMPLE 160
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 161
[3-Chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)--
phenoxy]acetic acid
EXAMPLE 162
[3-Chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-
-phenoxy]-acetic acid
EXAMPLE 163
[3-Chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)--
phenoxy]-acetic acid
EXAMPLE 164
[3-Chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-
-phenoxy]-acetic acid
EXAMPLE 165
[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ace-
tic acid
EXAMPLE 166
[3-Bromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]a-
cetic acid
EXAMPLE 167
[3-Bromo-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 168
[3-Bromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-(tri
fluoromethyl)phenoxy]acetic acid
EXAMPLE 169
[3-Bromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ac-
etic acid
EXAMPLE 170
[3-Bromo-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 171
[3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 172
[3-Bromo-4-[(3-pentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 173
[3-Bromo-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]acetic
acid
EXAMPLE 174
[3-Bromo-4-[(3-isobutyl-1H-indol-5-yl)oxyl-5-(trifluoromethyl)phenoxy]acet-
ic acid
EXAMPLE 175
[3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenoxy]ace-
tic acid
EXAMPLE 176
[3-Bromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-p-
henoxy]-acetic acid
EXAMPLE 177
[3-Bromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)--
phenoxy]-acetic acid
EXAMPLE 178
[3-Bromo-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-p-
henoxy]-acetic acid
EXAMPLE 179
[3-Bromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)--
phenoxy]-acetic acid
EXAMPLE 180
({4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}sulphanyl)acetic
acid
EXAMPLE 181
({3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}sulphanyl)acetic
acid
EXAMPLE 182
({3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}sulphanyl)acetic
acid
EXAMPLE 183
{[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]sulpha-
nyl}-acetic acid
EXAMPLE 184
{[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]su-
lphanyl}-acetic acid
EXAMPLE 185
({3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl)
sulphanyl)acetic acid
EXAMPLE 186
({3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl)
sulphanyl)acetic acid
EXAMPLE 187
({3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}sulphanyl)acet-
ic acid
EXAMPLE 188
{[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-.sup.5-(trifluoromethyl)pheny-
l]sulphanyl}-acetic acid
EXAMPLE 189
{[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]su-
lphanyl}-acetic acid
EXAMPLE 190
N-[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-(trifluoromethyl)phenyl]gly-
cine
EXAMPLE 191
N-[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]gl-
ycine
EXAMPLE 192
N-{3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}glycine
EXAMPLE 193
N-{3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}glycine
EXAMPLE 194
N-{3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}glycine
EXAMPLE 195
N-[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]g-
lycine
EXAMPLE 196
N-[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]glyci-
ne
EXAMPLE 197
N-{3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}glycine
EXAMPLE 198
N-{3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}glycine
EXAMPLE 199
N-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}glycine
EXAMPLE 200
3-{[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]-
amino}-3-oxopropionic acid
EXAMPLE 201
3-{[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]a-
mino}-3-oxopropionic acid
EXAMPLE 202
3-({3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl
}amino)-3-oxo-propionic acid
EXAMPLE 203
3-({3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-3-oxo-
propionic acid
EXAMPLE 204
3-({3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-3-ox-
o-propionic acid
EXAMPLE 205
3-([4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]-
amino}-3-oxopropionic acid
EXAMPLE 206
3-{[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]amin-
o) -3-oxopropionic acid
EXAMPLE 207
3-({3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl
}amino)-3-oxopropionic acid
EXAMPLE 208
3-({3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-3-oxoprop-
ionic acid
EXAMPLE 209
3-({4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}amino)-3-oxoprop-
ionic acid
EXAMPLE 210
3-{[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]-
amino}-2-oxopropionic acid
EXAMPLE 211
3-{[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]a-
mino}-2-oxopropionic acid
EXAMPLE 212
3-({3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-2-oxo-
propionic acid
EXAMPLE 213
3-({3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-2-oxo-
-propionic acid
EXAMPLE 214
3-({3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}amino)-2-ox-
o-propionic acid
EXAMPLE 215
3-{[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]-
amino}-2-oxopropionic acid
EXAMPLE 216
3-{[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]amin-
o}-2-oxopropionic acid
EXAMPLE 217
3-({3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-2-oxopropi-
onic acid
EXAMPLE 218
3-({3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}amino)-2-oxoprop-
ionic acid
EXAMPLE 219
3-({4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}amino)-2-oxoprop-
ionic acid
EXAMPLE 220
3-[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]p-
ropionic acid
EXAMPLE 221
3-[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]pr-
opionic acid
EXAMPLE 222
3-{3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}propionic
acid
EXAMPLE 223
3-{3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}propionic
acid
EXAMPLE 224
3-{3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl)propionic
acid
EXAMPLE 225
3-[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]--
propionic acid
EXAMPLE 226
3-[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]propi-
onic acid
EXAMPLE 227
3-{3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}propionic
acid
EXAMPLE 228
3-{3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}propionic
acid
EXAMPLE 229
3-{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}propionic
acid
EXAMPLE 230
[3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ace-
tic acid
EXAMPLE 231
[3-Chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]a-
cetic acid
EXAMPLE 232
[3-Chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ac-
etic acid
EXAMPLE 233
[3-Chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]a-
cetic acid
EXAMPLE 234
[3-Chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ac-
etic acid
EXAMPLE 235
[3-Chloro-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 236
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 237
[3-Chloro-4-[(3-pentyl-1H-indol-5-yl)oxy]
-5-(trifluoromethyl)phenyl]aceti- c acid
EXAMPLE 238
[3-Chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 239
[3-Chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acet-
ic acid
EXAMPLE 240
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-(trifluoromethyl)phenyl]ace-
tic acid
EXAMPLE 241
[3-Chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)p-
henyl]-acetic acid
EXAMPLE 242
[3-Chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-
phenyl]-acetic acid
EXAMPLE 243
[3-Chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)p-
henyl]-acetic acid
EXAMPLE 244
[3-Chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-
phenyl]-acetic acid
EXAMPLE 245
[4-[(3-Benzyl-1H-indol-5-yl)oxy]-3-chloro-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 246
[3-Chloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)phe-
nyl]-acetic acid
EXAMPLE 247
[3-Chloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)phe-
nyl]-acetic acid
EXAMPLE 248
[3-Chloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-(trifluor-
o-methyl)-phenyl]acetic acid
EXAMPLE 249
[3-Chloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-(trifluor-
o-methyl)-phenyl]acetic acid
EXAMPLE 250
[3-Chloro-4-([3-(phenylsulphonyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-p-
henyl]-acetic acid
EXAMPLE 251
[3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acet-
ic acid
EXAMPLE 252
[3-Bromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ac-
etic acid
EXAMPLE 253
[3-Bromo-4-[(3-cyclobutyl-l
H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ac- etic acid
EXAMPLE 254
[3-Bromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ac-
etic acid
EXAMPLE 255
[3-Bromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]ace-
tic acid
EXAMPLE 256
[3-Bromo-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 257
[3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 258
[3-Bromo-4-[(3-pentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 259
[3-Bromo-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 260
[3-Bromo-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]aceti-
c acid
EXAMPLE 261
[3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acet-
ic acid
EXAMPLE 262
[3-Bromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)ph-
enyl]-acetic acid
EXAMPLE 263
[3-Bromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)p-
henyl]-acetic acid
EXAMPLE 264
[3-Bromo-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)ph-
enyl]-acetic acid
EXAMPLE 265
[3-Bromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)--
phenyl]-acetic acid
EXAMPLE 266
[4-[(3-Benzyl-1H-indol-5-yl)oxy]-3-bromo-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 267
[3-Bromo-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)phen-
yl]-acetic acid
EXAMPLE 268
[3-Bromo-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)phen-
yl]-acetic acid
EXAMPLE 269
[3-Bromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-(trifluoro-
-methyl)-phenyl]acetic acid
EXAMPLE 270
[3-Bromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-(trifluoro-
-methyl)-phenyl]acetic acid
EXAMPLE 271
[3-Bromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)phe-
nyl]-acetic acid
EXAMPLE 272
{3-Bromo-5-chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 273
{3-Bromo-5-chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenyl
}acetic acid
EXAMPLE 274
{3-Bromo-5-chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 275
{3-Bromo-5-chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 276
{3-Bromo-5-chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 277
{3-Bromo-5-chloro-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 278
{3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-chlorophenyl}acetic
acid
EXAMPLE 279
{3-Bromo-5-chloro-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 280
{3-Bromo-5-chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 281
{3-Bromo-5-chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 282
{3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-chlorophenyl}acetic
acid
EXAMPLE 283
(3-Bromo-5-chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 284
(3-Bromo-5-chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenyl)aceti-
c acid
EXAMPLE 285
(3-Bromo-5-chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 286
(3-Bromo-5-chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy)
phenyl)acetic acid
EXAMPLE 287
{4-[(3-Benzyl-1H-indol-5-yl)oxy]-3-bromo-5-chlorophenyl}acetic
acid
EXAMPLE 288
(3-Bromo-5-chloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 289
(3-Bromo-5-chloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 290
[3-Bromo-5-chloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phen-
yl]-acetic acid
EXAMPLE 291
[3-Bromo-5-chloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phen-
yl]-acetic acid
EXAMPLE 292
(3-Bromo-5-chloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 293
{3-Bromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 294
{3-Bromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]-5-methylphenyl
}acetic acid
EXAMPLE 295
{3-Bromo-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 296
{3-Bromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 297
{3-Bromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 298
{3-Bromo-5-methyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 299
{3-Bromo-4-[(3-butyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 300
{3-Bromo-5-methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 301
{3-Bromo-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 302
{3-Bromo-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 303
{3-Bromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 304
(3-Bromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 305
(3-Bromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)aceti-
c acid
EXAMPLE 306
(3-Bromo-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 307
(3-Bromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)aceti-
c acid
EXAMPLE 308
{4-[(3-benzyl-1H-indol-5-yl)oxy]-3-bromo-5-methylphenyl}acetic
acid
EXAMPLE 309
(3-Bromo-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 310
(3-Bromo-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 311
[3-Bromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphen-
yl]-acetic acid
EXAMPLE 312
[3-Bromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphen-
yl]-acetic acid
EXAMPLE 313
(3-Bromo-5-methyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 314
{3-Chloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 315
(3-Chloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]
-5-methylphenyl}acetic acid
EXAMPLE 316
{3-Chloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 317
{3-Chloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 318
{3-Chloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 319
{3-Chloro-5-methyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 320
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenyl}acetic
acid
EXAMPLE 321
{3-Chloro-5-methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 322
{3-Chloro-4-[(3-hexyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 323
{3-Chloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]-5-methylphenyl}acetic
acid
EXAMPLE 324
{4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenyl}acetic
acid
EXAMPLE 325
(3-Chloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)aceti-
c acid
EXAMPLE 326
(3-Chloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acet-
ic acid
EXAMPLE 327
(3-Chloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy)
-5-methylphenyl)acetic acid
EXAMPLE 328
(3-Chloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acet-
ic acid
EXAMPLE 329
{4-[(3-Benzyl-1H-indol-5-yl)oxy]-3-chloro-5-methylphenyl}acetic
acid
EXAMPLE 330
(3-Chloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 331
(3-Chloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)acetic
acid
EXAMPLE 332
[3-Chloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphe-
nyl]-acetic acid
EXAMPLE 333
[3-Chloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphe-
nyl]-acetic acid
EXAMPLE 334
(3-Chloro-5-methyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 335
[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]ace-
tic acid
EXAMPLE 336
[4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]a-
cetic acid
EXAMPLE 337
[4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]ac-
etic acid
EXAMPLE 338
[4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]a-
cetic acid
EXAMPLE 339
[4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3-methyl-5-(tri
fluoromethyl)phenyl]acetic acid
EXAMPLE 340
[3-Methyl-4-[(3-propyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 341
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 342
[3-Methyl-4-[(3-pentyl-1H-indol-5-yl)oxy]-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 343
[4-[(3-Hexyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 344
[4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]acet-
ic acid
EXAMPLE 345
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]ace-
tic acid
EXAMPLE 346
[4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)p-
hen-yl]-acetic acid
EXAMPLE 347
[4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)-
-phenyl]-acetic acid
EXAMPLE 348
[4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)p-
henyl]-acetic acid
EXAMPLE 349
[4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)-
-phenyl]-acetic acid
EXAMPLE 350
[4-[(3-Benzyl-1H-indol-5-yl)oxy]-3-methyl-5-(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 351
[4-{[3-(4-Fluorobenzyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)phe-
nyl]-acetic acid
EXAMPLE 352
[4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3-methyl-5-(trifluoromethyl)phe-
nyl]-acetic acid
EXAMPLE 353
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3-methyl-5-(trifluor-
o-methyl)-phenyl]acetic acid
EXAMPLE 354
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3-methyl-5-(trifluor-
omethyl)-phenyl]acetic acid
EXAMPLE 355
[3-Methyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}-5-(trifluoromethyl)-p-
henyl]-acetic acid
EXAMPLE 356
[4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 357
[4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]aceti-
c acid
EXAMPLE 358
[4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 359
[4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]aceti-
c acid
EXAMPLE 360
[4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 361
[4-[(3-Propyl-1H-indol-5-yl)oxyl-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 362
[4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 363
[4-[(3-Pentyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 364
[4-[(3-Hexyl-1H-indol-5-yl)oxyl-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 365
[4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 366
[4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 367
[4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)pheny-
l]-acetic acid
EXAMPLE 368
[4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phen-
yl]-acetic acid
EXAMPLE 369
[4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy)
-3,5-bis(trifluoromethyl)phen- yl]-acetic acid
EXAMPLE 370
[4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phen-
yl]-acetic acid
EXAMPLE 371
[4-[(3-Benzyl-1H-indol-5-yl)oxy]-3,5-bis(trifluoromethyl)phenyl]acetic
acid
EXAMPLE 372
[4-{[3-(4-Fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl]-
acetic acid
EXAMPLE 373
[4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl]-
acetic acid
EXAMPLE 374
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-acetic acid
EXAMPLE 375
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-acetic acid
EXAMPLE 376
[4-{[3-(Phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl-
]acetic acid
EXAMPLE 377
{3,5-Dibromo-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 378
{3,5-Dibromo-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 379
{3,5-Dibromo-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 380
{3,5-Dibromo-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 381
{3,5-Dibromo-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 382
{3,5-Dibromo-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl) acetic acid
EXAMPLE 383
{3,5-Dibromo-4-[(3-butyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 384
{3,5-Dibromo-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 385
{3,5-Dibromo-4-[(3-hexyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 386
{3,5-Dibromo-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 387
(3,5-Dibromo-4-[(3-sec-butyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 388
(3,5-Dibromo-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 389
(3,5-Dibromo-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 390
(3,5-Dibromo-4-{[3-(cyclobutylmethyl)-1H-indo
1-5-yl]oxy}phenyl)acetic acid
EXAMPLE 391
(3,5-Dibromo-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 392
{4-[(3-Benzyl-1H-indol-5-yl)oxy]-3,5-dibromophenyl) acetic acid
EXAMPLE 393
(3,5-Dibromo-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 394
(3,5-Dibromo-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 395
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]ac-
etic acid
EXAMPLE 396
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]ac-
etic acid
EXAMPLE 397
(3,5-Dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 398
{3,5-Dichloro-4-[(3-isopropyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 399
{3,5-Dichloro-4-[(3-cyclopropyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 400
{3,5-Dichloro-4-[(3-cyclobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 401
{3,5-Dichloro-4-[(3-cyclopentyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 402
{3,5-Dichloro-4-[(3-cyclohexyl-1H-indol-5-yl)oxy]phenyl) acetic
acid
EXAMPLE 403
{3,5-Dichloro-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 404
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-dichlorophenyl}acetic acid
EXAMPLE 405
{3,5-Dichloro-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 406
{3,5-Dichloro-4-[(3-hexyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 407
{3,5-Dichloro-4-[(3-isobutyl-1H-indol-5-yl)oxy]phenyl}acetic
acid
EXAMPLE 408
{4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-dichlorophenyl}acetic
acid
EXAMPLE 409
(3,5-Dichloro-4-{[3-(cyclohexylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 410
(3,5-Dichloro-4-{[3-(cyclopentylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 411
(3,5-Dichloro-4-{[3-(cyclobutylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 412
(3,5-Dichloro-4-{[3-(cyclopropylmethyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 413
{4-[(3-Benzyl-1H-indol-5-yl)oxy]-3,5-dichlorophenyl}acetic acid
EXAMPLE 414
(3,5-Dichloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 415
(3,5-Dichloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 416
[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl
}oxy)phenyl]acetic acid
EXAMPLE 417
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 418
(3,5-Dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 419
{4-[(3-Isopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 420
{4-[(3-Cyclopropyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 421
{4-[(3-Cyclobutyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 422
{4-[(3-Cyclopentyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 423
{4-[(3-Cyclohexyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 424
{3,5-Dimethyl-4-[(3-propyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 425
{4-[(3-Butyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic acid
EXAMPLE 426
{3,5-Dimethyl-4-[(3-pentyl-1H-indol-5-yl)oxy]phenyl}acetic acid
EXAMPLE 427
{4-[(3-Hexyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic acid
EXAMPLE 428
{4-[(3-Isobutyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl) acetic
acid
EXAMPLE 429
{4-[(3-sec-Butyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic
acid
EXAMPLE 430
(4-{[3-(Cyclohexylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 431
(4-{[3-(Cyclopentylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 432
(4-{[3-(Cyclobutylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 433
(4-{[3-(Cyclopropylmethyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 434
{4-[(3-Benzyl-1H-indol-5-yl)oxy]-3,5-dimethylphenyl}acetic acid
EXAMPLE 435
(4-{[3-(4-Fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 436 (
4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 437
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]a-
cetic acid
EXAMPLE 438
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]a-
cetic acid
EXAMPLE 439
(3,5-Dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 440
(3,5-Dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 441
(3,5-Dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 442
(3,5-Dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 443
[4-{[3-(Phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenox-
y]-acetic acid
EXAMPLE 444
(3,5-Dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 445
3,5-Dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 446
(3,5-Dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 447
[4-{[3-(Phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl-
]acetic acid
EXAMPLE 448
3,5-Dimethyl-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 449
3,5-Dichloro-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 450
3,5-Dibromo-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 451
O-[3-(Phenylsulphonyl)-1H-indol-5-yl]-3,5-bis(trifluoromethyl)-D-tyrosine
EXAMPLE 452
3,5-Dimethyl-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 453
3,5-Dichloro-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 454
3,5-Dibromo-O-[3-(phenylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 455
O-[3-(phenylsulphonyl)-1H-indol-5-yl]-3,5-bis(trifluoromethyl)-L-tyrosine
EXAMPLE 456
(3,5-Dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)methane-sul-
phonic acid
EXAMPLE 457
(3,5-Dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)methanesulp-
honic acid
EXAMPLE 458
(3,5-Dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)methanesulph-
onic acid
EXAMPLE 459
[4-{[3-(Phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl-
]-methanesulphonic acid
EXAMPLE 460
[(3,5-Dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulphanyl]-
acetic acid
EXAMPLE 461
[(3,5-Dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulphanyl]-
acetic acid
EXAMPLE 462
[(3,5-Dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulphanyl]a-
cetic acid
EXAMPLE 463
{[4-{[3-(Phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)pheny-
l]-sulphanyl}-acetic acid
EXAMPLE 464
(2R)-Amino(3,5-dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy)
phenyl)-ethanoic acid
EXAMPLE 465
(2R)-Amino(3,5-dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)--
ethanoic acid
EXAMPLE 466
(2R)-Amino(3,5-dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)-e-
thanoic acid
EXAMPLE 467
(2R)-Amino[4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromet-
hyl)-phenyl]ethanoic acid
EXAMPLE 468
(2S)-Amino(3,5-dimethyl-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)--
ethanoic acid
EXAMPLE 469
(2S)-Amino(3,5-dichloro-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)--
ethanoic acid
EXAMPLE 470
(2S)-Amino(3,5-dibromo-4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy}phenyl)-e-
thanoic acid
EXAMPLE 471
(2S)-Amino[4-{[3-(phenylsulphonyl)-1H-indol-5-yl]oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]ethanoic acid
EXAMPLE 472
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenoxy]-
acetic acid
EXAMPLE 473
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]-
acetic acid
EXAMPLE 474
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]a-
cetic acid
EXAMPLE 475
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenoxy]-acetic acid
EXAMPLE 476
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl
}oxy)-3,5-dimethylphenyl]- acetic acid
EXAMPLE 477
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 478
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]ac-
etic acid
EXAMPLE 479
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-acetic acid
EXAMPLE 480
O-{3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl
}-3,5-dimethyl-D-tyrosine
EXAMPLE 481
3,5-Dichloro-O-{3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 482
3,5-Dibromo-O-{3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 483
O-{3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl
}-3,5-bis(trifluoromethyl)-- D-tyrosine
EXAMPLE 484
O-{3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-dimethyl-L-tyrosine
EXAMPLE 485
3,5-Dichloro-O-{3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 486
3,5-Dibromo-O-{3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl-L-tyrosine
EXAMPLE 487
O-{3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)-L-
-tyrosine
EXAMPLE 488
[4-({3-[(4-Fluorphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]me-
thane-sulphonic acid
EXAMPLE 489
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
methane-sulphonic acid
EXAMPLE 490
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-m-
ethane-sulphonic acid
EXAMPLE 491
[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-methanesulphonic acid
EXAMPLE 492
{[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]-
-sulphanyl}-acetic acid
EXAMPLE 493
{[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
sulphanyl}-acetic acid
EXAMPLE 494
([3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]s-
ulphanyl}-acetic acid
EXAMPLE 495
{[4-({3-[(4-Fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenyl]-sulphanyl}acetic acid
EXAMPLE 496
(2R)-Amino[4-(
(3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimet-
hyl-phenyl]-ethanoic acid
EXAMPLE 497
(2R)-Amino[3,5-dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]-ethanoic acid
EXAMPLE 498
(2R)-Amino[3,5-dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy-
)-phenyl]-ethanoic acid
EXAMPLE 499
(2R)-Amino[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
i-fluoro-methyl)phenyl]ethanoic acid
EXAMPLE 500
(2S)-Amino[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimeth-
yl-phenyl]-ethanoic acid
EXAMPLE 501
(2S)-Amino[3,5-dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]-ethanoic acid
EXAMPLE 502
(2S)-Amino [3,5-dibromo-4-(
(3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}o-
xy)-phenyl]-ethanoic acid
EXAMPLE 503
(2S)-Amino[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
ifluoro-methyl)phenyl]ethanoic acid
EXAMPLE 504
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl)
oxy)-3,5-dimethylphenoxy- ]acetic acid
EXAMPLE 505
[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]-
acetic acid
EXAMPLE 506
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]a-
cetic acid
EXAMPLE 507
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenoxy]-acetic acid
EXAMPLE 508
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]a-
cetic acid
EXAMPLE 509
[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 510
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]ac-
etic acid
EXAMPLE 511
[4-(
(3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenyl]-acetic acid
EXAMPLE 512
O-{3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-dimethyl-D-tyrosine
EXAMPLE 513
3,5-Dichloro-O-{3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 514
3,5-Dibromo-O-{3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl
}-D-tyrosine
EXAMPLE 515
O-{3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)-D-
-tyrosine
EXAMPLE 516
O-{3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-dimethyl-L-tyrosine
EXAMPLE 517
3,5-Dichloro-O-{3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 518
3,5-Dibromo-O-{3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 519
O-{3-((4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)-L-
-tyrosine
EXAMPLE 520
[4-({3-[(4-Clorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]-m-
ethane-sulphonic acid
EXAMPLE 521
[3,5-Dichloro-4-(
(3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
-methane-sulphonic acid
EXAMPLE 522
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-m-
ethane-sulphonic acid
EXAMPLE 523
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-methanesulphonic acid
EXAMPLE 524
{[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]-
-sulphanyl}-acetic acid
EXAMPLE 525
{[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
sulphanyl}-acetic acid
EXAMPLE 526
{[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]s-
ulphanyl}-acetic acid
EXAMPLE 527
{[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl)-oxy)-3,5-bis(trifluorom-
ethyl)-phenyl]-sulphanyl}acetic acid
EXAMPLE 528
(2R)-Amino[4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimeth-
yl-phenyl]ethanoic acid
EXAMPLE 529
(2R)-Amino[3,5-dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]ethanoic acid
EXAMPLE 530
(2R)-Amino[3,5-dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy-
)-phenyl]ethanoic acid
EXAMPLE 531
(2R)-Amino[4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
ifluoro-methyl)phenyl]ethanoic acid
EXAMPLE 532
(2S)-Amino[4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimeth-
yl-phenyl]ethanoic acid
EXAMPLE 533
(2S)-Amino[3,5-dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]ethanoic acid
EXAMPLE 534
(2S)-Amino[3,5-dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy-
)-phenyl]ethanoic acid
EXAMPLE 535
(2S)-Amino[4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
i-fluoro-methyl)phenyl]ethanoic acid
EXAMPLE 536
[3,5-Dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]-
-acetic acid
EXAMPLE 537
[3,5-Dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]-
acetic acid
EXAMPLE 538
[3,5-Dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl)
oxy)phenoxy]acetic acid
EXAMPLE 539
[4-({3-[(4-Methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenoxy]acetic acid
EXAMPLE 540
[3,5-Dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 541
[3,5-Dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 542
[3,5-Dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]ac-
etic acid
EXAMPLE 543
[4-({3-[(4-Methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-acetic acid
EXAMPLE 544
3,5-Dimethyl-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 545
3,5-Dichloro-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 546
3,5-Dibromo-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl
}-D-tyrosine
EXAMPLE 547
O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)-D-
-tyrosine
EXAMPLE 548
3,5-Dimethyl-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 549
3,5-Dichloro-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 550
3,5-Dibromo-O-{3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 551
O-{3-[(4-Methylphenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)-L-
-tyrosine
EXAMPLE 552
[3,5-Dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
methane-sulphonic acid
EXAMPLE 553
[3,5-Dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
methane-sulphonic acid
EXAMPLE 554
[3,5-Dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-m-
ethane-sulphonic acid
EXAMPLE 555
[4-({3-[(4-Methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-methanesulphonic acid
EXAMPLE 556
{[3,5-Dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
-sulphanyl}acetic acid
EXAMPLE 557
{[3,5-Dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
-sulphanyl}-acetic acid
EXAMPLE 558
{[3,5-Dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
sulphanyl}-acetic acid
EXAMPLE 559
{[4-({3-[(4-Methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenyl]sulphanyl}acetic acid
EXAMPLE 560
(2R)-Amino[3,5-dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl
}oxy)-phenyl]ethanoic acid
EXAMPLE 561
(2R)-Amino[3,5-dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl
}oxy)-phenyl]ethanoic acid
EXAMPLE 562
(2R)-Amino[3,5-dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy-
)-phenyl]ethanoic acid
EXAMPLE 563
(2R)-Amino[4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
ifluoro-methyl)phenyl]ethanoic acid
EXAMPLE 564
(2S)-Amino[3,5-dimethyl-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]ethanoic acid
EXAMPLE 565
(2S)-Amino[3,5-dichloro-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]-ethanoic acid
EXAMPLE 566
(2S)-Amino[3,5-dibromo-4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy-
)-phenyl]ethanoic acid
EXAMPLE 567
(2S)-Amino[4-({3-[(4-methylphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(tr-
i-fluoro-methyl)phenyl]ethanoic acid
EXAMPLE 568
(3,5-Dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)aceti-
c acid
EXAMPLE 569
(3,5-Dichloro-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)aceti-
c acid
EXAMPLE 570
(3,5-Dibromo-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenoxy)acetic
acid
EXAMPLE 571
[4-{[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)p-
henoxy]-acetic acid
EXAMPLE 572
(3,5-Dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 573
(3,5-Dichloro-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy)
phenyl)acetic acid
EXAMPLE 574
(3,5-Dibromo-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)acetic
acid
EXAMPLE 575
[4-{[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)p-
henyl]-acetic acid
EXAMPLE 576
3,5-Dimethyl-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 577
3,5-Dichloro-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 578
3,5-Dibromo-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-D-tyrosine
EXAMPLE 579
O-[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]-3,5-bis(trifluoromethyl)-D-tyro-
sine
EXAMPLE 580
3,5-Dimethyl-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 581
3,5-Dichloro-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 582
3,5-Dibromo-O-[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]-L-tyrosine
EXAMPLE 583
O-[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]-3,5-bis(trifluoromethyl)-L-tyro-
sine
EXAMPLE 584
(3,5-Dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)methan-
e-sulphonic acid
EXAMPLE 585
(3,5-Dichloro-4-{(3-(4-pyridinyisulphonyl)-1H-indol-5-yl]oxy}phenyl)methan-
e-sulphonic acid
EXAMPLE 586
(3,5-Dibromo-4-{[3-(4-pyndinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)methane--
sulphonic acid
EXAMPLE 587
[4-{[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)p-
henyl]-methanesulphonic acid
EXAMPLE 588
[(3,5-Dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulph-
anyl]-acetic acid
EXAMPLE 589
[(3,5-Dichloro-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulph-
anyl]-acetic acid
EXAMPLE 590
[(3,5-Dibromo-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phenyl)sulpha-
nyl]-acetic acid
EXAMPLE 591
{[4-{[3-(4-Pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)-
phenyl]-sulphanyl}acetic acid
EXAMPLE 592
(2R)-Amino(3,5-dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phe-
nyl)-ethanoic acid
EXAMPLE 593
(2R)-Amino(3,5-dichloro-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phe-
nyl)-ethanoic acid
EXAMPLE 594
(2R)-Amino(3,5-dibromo-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phen-
yl)-ethanoic acid
EXAMPLE 595
(2R)-Amino
[4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(triflu-
oro-methyl)-phenyl]ethanoic acid
EXAMPLE 596
(2S)-Amino(3,5-dimethyl-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phe-
nyl)-ethanoic acid
EXAMPLE 597
(2S)-Amino(3,5-dichloro-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phe-
nyl)-ethanoic acid
EXAMPLE 598
(2S)-Amino(3,5-dibromo-4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}phen-
yl)-ethanoic acid
EXAMPLE 599
(2S)-Amino[4-{[3-(4-pyridinylsulphonyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluo-
ro-methyl)-phenyl]ethanoic acid
EXAMPLE 600
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenoxy-
]-acetic acid
EXAMPLE 601
[3,5-Dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy-
]-acetic acid
EXAMPLE 602
[3,5-Dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenoxy]-
-acetic acid
EXAMPLE 603
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenoxy]acetic acid
EXAMPLE 604
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]-
-acetic acid
EXAMPLE 605
[3,5-Dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
acetic acid
EXAMPLE 606
[3,5-Dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]a-
cetic acid
EXAMPLE 607
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenyl]acetic acid
EXAMPLE 608
O-{3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}-3,5-dimethyl-D-tyrosine
EXAMPLE 609
3,5-Dichloro-O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 610
3,5-Dibromo-O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-D-tyrosine
EXAMPLE 611
O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)--
D-tyrosine
EXAMPLE 612
O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-3,5-dimethyl-L-tyrosine
EXAMPLE 613
3,5-Dichloro-O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 614
3,5-Dibromo-O-{3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}-L-tyrosine
EXAMPLE 615
O-{3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}-3,5-bis(trifluoromethyl)--
L-tyrosine
EXAMPLE 616
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl
}oxy)-3,5-dimethylphenyl- ]-methane-sulphonic acid
EXAMPLE 617
[3,5-Dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl)
oxy)phenyl]-methane-sulphonic acid
EXAMPLE 618
[3,5-Dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
methane-sulphonic acid
EXAMPLE 619
[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorome-
thyl)-phenyl]methanesulphonic acid
EXAMPLE 620
{[4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl-
]-sulphanyl}acetic acid
EXAMPLE 621
{[3,5-Dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl-
]-sulphanyl}acetic acid
EXAMPLE 622
{[3,5-Dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-
-sulphanyl}acetic acid
EXAMPLE 623
([4-({3-[(4-Methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluorom-
ethyl)-phenyl]sulphanyl}acetic acid
EXAMPLE 624
(2R)-Amino[4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimet-
hyl-phenyl]ethanoic acid
EXAMPLE 625
(2R)-Amino[3,5-dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}o-
xy)-phenyl]ethanoic acid
EXAMPLE 626
(2R)-Amino[3,5-dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]ethanoic acid
EXAMPLE 627
(2R)-Amino[4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(t-
rifluoro-methyl)phenyl]ethanoic acid
EXAMPLE 628
(2S)-Amino[4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimet-
hyl-phenyl]ethanoic acid
EXAMPLE 629
(2S)-Amino[3,5-dichloro-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}o-
xy)-phenyl]ethanoic acid
EXAMPLE 630
(2S)-Amino[3,5-dibromo-4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}ox-
y)-phenyl]ethanoic acid
EXAMPLE 631
(2S)-Amino[4-({3-[(4-methoxyphenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(t-
rifluoro-methyl)phenyl]ethanoic acid
EXAMPLE 632
{3,5-Dimethyl-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)oxy]-phenoxy}acetic acid
EXAMPLE 633
{3,5-Dichloro-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl)
-1H-indol-5-yl)oxy]-phenoxy}acetic acid
EXAMPLE 634
{3,5-Dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)oxy]-phenoxy}acetic acid
EXAMPLE 635
{3,5-Bis(trifluoromethyl)-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H--
indol-5-yl)oxy]-phenoxy}acetic acid
EXAMPLE 636
{3,5-Dimethyl-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)o-
xy]-phenyl}-acetic acid
EXAMPLE 637
{3,5-Dichloro-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)o-
xy]-phenyl}-acetic acid
EXAMPLE 638
{3,5-Dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)ox-
y]-phenyl}-acetic acid
EXAMPLE 639
{3,5-Bis(trifluoromethyl)-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl)
-1H-indol-5-yl)oxy]-phenyl}acetic acid
EXAMPLE 640
3,5-Dimethyl-O-(3-([4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)-D-tyrosine
EXAMPLE 641
3,5-Dichloro-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)-D-tyrosine
EXAMPLE 642
3,5-Dibromo-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)-D-t-
yrosine
EXAMPLE 643
3,5-Bis(trifluoromethyl)-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-in-
dol-5-yl)-D-tyrosine
EXAMPLE 644
3,5-Dimethyl-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)-L-tyrosine
EXAMPLE 645
3,5-Dichloro-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)-L-tyrosine
EXAMPLE 646
3,5-Dibromo-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl)
-1H-indol-5-yl)-L-tyrosine
EXAMPLE 647
3,5-Bis(trifluoromethyl)-O-(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-in-
dol-5-yl)-L-tyrosine
EXAMPLE 648
(3,5-Dimethyl-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)o-
xy]-phenyl}-methanesulphonic acid
EXAMPLE 649
(3,5-Dichloro-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)o-
xy]-phenyl}-methanesulphonic acid
EXAMPLE 650
{3,5-Dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)ox-
y]-phenyl}-methanesulphonic acid
EXAMPLE 651
{3,5-Bis(trifluoromethyl)-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl
}-1H-indol-5-yl)oxy]phenyl }methanesulphonic acid
EXAMPLE 652
({3,5-Dimethyl-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)-
oxy]-phenyl}sulphanyl)acetic acid
EXAMPLE 653
({3,5-Dichloro-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)-
oxy]-phenyl}sulphanyl)acetic acid
EXAMPLE 654
({3,5-Dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-indol-5-yl)o-
xy]-phenyl}sulphanyl)acetic acid
EXAMPLE 655
({3,5-Bis(trifluoromethyl)-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-
-indol-5-yl)oxy]-phenyl}sulphanyl)acetic acid
EXAMPLE 656
(2R)-Amino {3,5-dimethyl-4-[(3-{[4-(tri
fluoromethyl)phenyl]sulphonyl }-1H-indol-5-yl)oxy]phenyl}ethanoic
acid
EXAMPLE 657
(2R)-Amino
(3,5-dichloro-4-((3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-i-
ndol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 658
(2R)-Amino
{3,5-dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-in-
dol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 659
(2R)-Amino{3,5-bis(trifluoromethyl)-4-[(3-{[4-(trifluoromethyl)phenyl]sulp-
honyl}-1H-indol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 660
(2S)-Amino
{3,5-dimethyl-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-i-
ndol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 661
(2S)-Amino
{3,5-dichloro-4-[(3-([4-(trifluoromethyl)phenyl]sulphonyl}-1H-i-
ndol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 662
(2S)-Amino
{3,5-dibromo-4-[(3-{[4-(trifluoromethyl)phenyl]sulphonyl}-1H-in-
dol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 663
(2S)-Amino
(3,5-bis(trifluoromethyl)-4-((3-{[4-(trifluoromethyl)phenyl]sul-
phonyl}-1H-indol-5-yl)oxy]phenyl}ethanoic acid
EXAMPLE 664
Difluoro(4-([3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acet-
ic acid
EXAMPLE 665
(4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)(difluoro)ac-
etic acid
EXAMPLE 666
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]--
(difluoro)-acetic acid
EXAMPLE 667
Difluoro[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethyl-
-phenyl]-acetic acid
EXAMPLE 668
Fluoro[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylph-
enyl]acetic acid
EXAMPLE 669
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-dimethylphenyl]--
(fluoro)-acetic acid
EXAMPLE 670
(4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)(fluoro)acet-
ic acid
EXAMPLE 671
Fluoro(4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-dimethylphenyl)acetic
acid
EXAMPLE 672
(3-Chloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)(fluoro-
)acetic acid
EXAMPLE 673
(3-Chloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)(fluoro-
)acetic acid
EXAMPLE 674
[3-Chloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphe-
nyl]-(fluoro)-acetic acid
EXAMPLE 675
3-Chloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphen-
yl]-(fluoro)-acetic acid
EXAMPLE 676
[3-Chloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphe-
nyl]-(difluoro)acetic acid
EXAMPLE 677
[3-Chloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-5-methylphe-
nyl]-(difluoro)acetic acid
EXAMPLE 678
(3-Chloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)(difluo-
ro)-acetic acid
EXAMPLE 679
(3-Chloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-5-methylphenyl)(difluo-
ro)-acetic acid
EXAMPLE 680
(3,5-Dichloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)(difluoro)ac-
etic acid
EXAMPLE 681
(3,5-Dichloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)(difluoro)ac-
etic acid
EXAMPLE 682
[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
(difluoro)-acetic acid
EXAMPLE 683
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]--
(difluoro)-acetic acid
EXAMPLE 684
[3,5-Dichloro-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl](-
fluoro)-acetic acid
EXAMPLE 685
[3,5-Dichloro-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl](-
fluoro)-acetic acid
EXAMPLE 686
(3,5-Dichloro-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)(fluoro)acet-
ic acid
EXAMPLE 687
(3,5-Dichloro-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)(fluoro)acet-
ic acid
EXAMPLE 688
(3,5-Dibromo-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)(fluoro)aceti-
c acid
EXAMPLE 689
(3,5-Dibromo-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)(fluoro)aceti-
c acid
EXAMPLE 690
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-(-
fluoro)-acetic acid
EXAMPLE 691
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl](f-
luoro)-acetic acid
EXAMPLE 692
[3,5-Dibromo-4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-(-
difluoro)-acetic acid
EXAMPLE 693
[3,5-Dibromo-4-({3-[(4-chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)phenyl]-(-
difluoro)-acetic acid
EXAMPLE 694
(3,5-Dibromo-4-{[3-(4-chlorobenzyl)-1H-indol-5-yl]oxy}phenyl)(difluoro)ace-
tic acid
EXAMPLE 695
(3,5-Dibromo-4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}phenyl)(difluoro)ace-
tic acid
EXAMPLE 696
Difluoro[4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl-
)phenyl]-acetic acid
EXAMPLE 697
[4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl]-
-(difluoro)-acetic acid
EXAMPLE 698
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trifluoromet-
hyl)-phenyl]-(difluoro)acetic acid
EXAMPLE 699
Difluoro[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(trif-
luoro-methyl)-phenyl]acetic acid
EXAMPLE 700
Fluoro[4-({3-[(4-fluorophenyl)sulphonyl]-1H-indol-5-yl}oxy)-3,5-bis(triflu-
oro-methyl)-phenyl]acetic acid
EXAMPLE 701
[4-({3-[(4-Chlorophenyl)sulphonyl]-1H-indol-5-yl
}oxy)-3,5-bis(trifluorome- thyl)-phenyl]-(fluoro)acetic acid
EXAMPLE 702
[4-{[3-(4-Chlorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)phenyl]-
-(fluoro)acetic acid
EXAMPLE 703
Fluoro[4-{[3-(4-fluorobenzyl)-1H-indol-5-yl]oxy}-3,5-bis(trifluoromethyl)p-
henyl]-acetic acid
[0508]
Sequence CWU 1
1
6 1 19 DNA Artificial Primer 1 gggaatcgac tccgaggtc 19 2 20 DNA
Artificial Primer 2 gatcttggtg aaacgcacga 20 3 23 DNA Artificial
Probe 3 acaagacggc ccgtgcacta cgc 23 4 20 DNA Artificial Primer 4
cgaggtgctg gaggaatacc 20 5 21 DNA Artificial Primer 5 ctagccggtc
aatagccaca g 21 6 22 DNA Artificial Probe 6 catgatgcgg cgtgcctttg
ag 22
* * * * *